EX-2.1
Published on November 18, 2026
Exhibit 2.1
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. [***] denotes omissions.
Execution Version
ASSET PURCHASE AGREEMENT
between
ELLODI PHARMACEUTICALS, L.P.
and
ABEONA THERAPEUTICS INC.
dated as of November 6, 2026
TABLE OF CONTENTS
| ARTICLE I DEFINITIONS | 1 |
| ARTICLE II PURCHASE AND SALE | 12 |
| Section 2.01 Purchase and Sale of Assets. | 12 |
| Section 2.02 Excluded Assets. | 13 |
| Section 2.03 Assumed Liabilities. | 14 |
| Section 2.04 Excluded Liabilities. | 14 |
| Section 2.05 Purchase Price. | 16 |
| Section 2.06 Allocation of Purchase Price. | 16 |
| Section 2.07 Withholding Tax. | 16 |
| Section 2.08 Third Party Consents. | 17 |
| Section 2.09 Royalties. | 17 |
| Section 2.10 Milestone Payments. | 18 |
| Section 2.11 Lockup; Registration Rights. | 20 |
| ARTICLE III CLOSING | 21 |
| Section 3.01 Closing. | 21 |
| Section 3.02 Closing Deliverables. | 21 |
| ARTICLE IV REPRESENTATIONS AND WARRANTIES OF SELLER | 22 |
| Section 4.01 Organization and Qualification of Seller. | 22 |
| Section 4.02 Authority of Seller. | 22 |
| Section 4.03 No Conflicts; Consents. | 23 |
| Section 4.04 Financial Statements. | 23 |
| Section 4.05 Undisclosed Liabilities. | 23 |
| Section 4.06 Absence of Certain Changes, Events and Conditions. | 23 |
| Section 4.07 Material Contracts. | 24 |
| Section 4.08 Title to Acquired Assets. | 25 |
| Section 4.09 Condition and Sufficiency of Assets. | 25 |
| -ii- |
| Section 4.10 Intellectual Property. | 25 |
| Section 4.11 Inventory. | 27 |
| Section 4.12 Customers and Suppliers. | 27 |
| Section 4.13 Insurance. | 28 |
| Section 4.14 Legal Proceedings; Governmental Orders. | 28 |
| Section 4.15 Compliance With Laws; Regulatory Authorizations. | 28 |
| Section 4.16 Environmental Matters. | 28 |
| Section 4.17 FDA Matters. | 29 |
| Section 4.18 Employee Benefit Matters. | 34 |
| Section 4.19 Employment Matters. | 34 |
| Section 4.20 Taxes. | 35 |
| Section 4.21 Related Party Transactions. | 36 |
| Section 4.22 Data Privacy and Cybersecurity. | 36 |
| Section 4.23 CFIUS. | 36 |
| Section 4.24 Anti-Corruption. | 37 |
| Section 4.25 Securities Laws. | 38 |
| Section 4.26 Material Product Information. | 38 |
| Section 4.27 Brokers. | 38 |
| Section 4.28 No Other Representations. | 38 |
| ARTICLE V REPRESENTATIONS AND WARRANTIES OF BUYER | 39 |
| Section 5.01 Organization of Buyer. | 39 |
| Section 5.02 Authority of Buyer. | 39 |
| Section 5.03 No Conflicts; Consents. | 39 |
| Section 5.04 Brokers. | 39 |
| Section 5.05 Buyer SEC Reports. | 40 |
| Section 5.06 No Governmental Approval. | 40 |
| Section 5.07 Upfront Shares. | 40 |
| -iii- |
| Section 5.08 Legal Proceedings. | 40 |
| Section 5.09 Sanctions. | 40 |
| Section 5.10 Not a Person of a Country of Concern. | 40 |
| Section 5.11 CFIUS Representations. | 41 |
| Section 5.12 Anticorruption. | 41 |
| ARTICLE VI COVENANTS | 41 |
| Section 6.01 Employees and Employee Benefits. | 41 |
| Section 6.02 Confidentiality. | 42 |
| Section 6.03 Non-Competition; Non-Solicitation. | 42 |
| Section 6.04 Books and Records. | 43 |
| Section 6.05 Public Announcements. | 43 |
| Section 6.06 Bulk Sales Laws. | 44 |
| Section 6.07 Payments Received After Closing. | 44 |
| Section 6.08 Transfer Taxes. | 44 |
| Section 6.09 Control and Development of Products; Transition Plan. | 44 |
| Section 6.10 Further Assurances. | 44 |
| Section 6.11 IND Transfer. | 44 |
| ARTICLE VIII INDEMNIFICATION | 45 |
| Section 8.01 Survival. | 45 |
| Section 8.02 Indemnification By Seller. | 45 |
| Section 8.03 Indemnification By Buyer. | 46 |
| Section 8.04 Certain Limitations. | 46 |
| Section 8.05 Indemnification Procedures. | 47 |
| Section 8.06 Payments; Indemnification Set-Off. | 48 |
| Section 8.07 Tax Treatment of Indemnification Payments. | 49 |
| Section 8.08 Application of Indemnification upon Distribution. | 49 |
| Section 8.09 Exclusive Remedies. | 50 |
| ARTICLE IX TERMINATION | 50 |
| ARTICLE X MISCELLANEOUS | 50 |
| Section 10.01 Expenses. | 50 |
| Section 10.02 Notices. | 51 |
| Section 10.03 Interpretation. | 51 |
| Section 10.04 Headings. | 51 |
| Section 10.05 Severability. | 52 |
| Section 10.06 Entire Agreement. | 52 |
| Section 10.07 Successors and Assigns. | 52 |
| Section 10.08 No Third-Party Beneficiaries. | 52 |
| Section 10.09 Amendment and Modification; Waiver. | 52 |
| Section 10.10 Governing Law; Submission to Jurisdiction; Waiver of Jury Trial. | 52 |
| Section 10.11 Specific Performance. | 53 |
| Section 10.12 Non-Reliance. | 53 |
| Section 10.13 Counterparts. | 53 |
| -iv- |
ASSET PURCHASE AGREEMENT
This Asset Purchase Agreement (this “Agreement”), dated as of November 6, 2026, is entered into between ELLODI PHARMACEUTICALS, L.P., a Delaware limited partnership (“Seller”) and ABEONA THERAPEUTICS INC., a Delaware corporation (“Buyer”).
Recitals
WHEREAS, Seller is a specialty, single-asset pharmaceutical company engaged in the development, manufacture, and commercialization of APT-1011 (as defined herein) (the “Business”); and
WHEREAS, Seller wishes to sell and assign to Buyer, and Buyer wishes to purchase and assume from Seller, certain specified assets and certain specified liabilities relating to the Business and the Products (as defined herein), subject to the terms and conditions set forth herein.
NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
ARTICLE I
Definitions
The following terms have the meanings specified or referred to in this Article I:
“Abeona Common Stock” means the common stock, par value $0.01 per share, of Buyer.
“Acquired Assets” has the meaning set forth in Section 2.01.
“Action” means any claim, action, cause of action, demand, lawsuit, arbitration, inquiry, audit, notice of violation, proceeding, litigation, citation, summons, subpoena, or investigation of any nature, civil, criminal, administrative, regulatory, or otherwise, whether at law or in equity.
“Affiliate” of a Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such Person. The term “control” (including the terms “controlled by” and “under common control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.
“Agreement” has the meaning set forth in the preamble.
“Allocation Schedule” has the meaning set forth in Section 2.06.
“Ancillary Documents” means the Bill of Sale, Intellectual Property Assignments, the Registration Rights Agreement, and the other agreements, instruments and documents required to be delivered at the Closing.
“Anti-Corruption Laws” has the meaning set forth in Section 4.24(b).
“Applicable Regulatory Laws” has the meaning set forth in Section 4.17(b).
“APT-1011” means that certain pharmaceutical product identified as APT-1011 in IND No. 110829, including the orally disintegrating tablet formulation containing fluticasone propionate as the active pharmaceutical ingredient and all strengths, formulations, dosage forms, presentations, improvements, modifications, and line extensions described in, covered by, or developed pursuant to such IND, any related regulatory filings, and any NDA or other marketing authorization arising therefrom.
“Assigned Contracts” has the meaning set forth in Section 2.01(f).
“Assumed Liabilities” has the meaning set forth in Section 2.03.
“Balance Sheet” has the meaning set forth in Section 4.04.
“Balance Sheet Date” has the meaning set forth in Section 4.04.
“Basket” has the meaning set forth in Section 8.04(a).
“Benefit Plan” has the meaning set forth in Section 4.18(a).
“Bill of Sale” has the meaning set forth in Section 3.02(a)(i).
“Business” has the meaning set forth in the Recitals.
“Business Day” means any day except Saturday, Sunday, or any other day on which commercial banks located in New York, New York are authorized or required by Law to be closed for business.
“Buyer” has the meaning set forth in the preamble.
“Buyer Indemnitees” has the meaning set forth in Section 8.02.
“Buyer’s Accountants” means Deloitte & Touche LLP.
“Closing” has the meaning set forth in Section 3.01.
“Closing Date” has the meaning set forth in Section 3.01.
“Closing Shares” has the meaning set forth in Section 2.11(a).
“Closing Stock Price” has the meaning set forth in Section 2.05.
“CMC” has the meaning set forth in Section 2.01(e).
“COBRA” has the meaning set forth in Section 4.18(d).
“Code” means the Internal Revenue Code of 1986, as amended.
| -2- |
“Combination Product” means a Product that is sold, whether packaged together or as a single formulation, with one or more other active pharmaceutical ingredients or products that are not themselves a Product.
“Commercially Reasonable Efforts” means that level of efforts and resources consistent with the efforts and resources applied by a similarly situated biopharmaceutical company of similar size and resources to carry out a particular task or obligation with respect to a compound, product, or therapy of similar scientific and market potential at a similar stage of development or product life, taking into account all relevant factors, including issues of safety and efficacy, product profile, the proprietary position, the then-current competitive environment, the regulatory status and approval process, and the anticipated profitability of the applicable product (but excluding payments to be made to Seller hereunder).
“Contracts” means all contracts, leases, deeds, mortgages, licenses, instruments, notes, commitments, undertakings, indentures, joint ventures and all other agreements, commitments, and legally binding arrangements, whether written or oral.
“Copyrights” has the meaning set forth in the definition of Intellectual Property.
“Direct Claim” has the meaning set forth in Section 8.05(c).
“Disclosure Schedules” means the Disclosure Schedules delivered by Seller concurrently with the execution and delivery of this Agreement.
“Distribution” has the meaning set forth in Section 2.11(c).
“Distribution Joinder” has the meaning set forth in Section 2.11(c).
“Distribution Recipient” has the meaning set forth in Section 2.11(c).
“Dollars” or “$” means the lawful currency of the United States.
“DPA” has the meaning set forth in Section 4.23.
“EMA” has the meaning set forth in Section 4.17(f).
“Encumbrance” means any charge, claim, community property interest, pledge, condition, equitable interest, lien (statutory or other), option, security interest, mortgage, easement, encroachment, right of way, right of first refusal, or restriction of any kind, including any restriction on use, voting, transfer, receipt of income or exercise of any other attribute of ownership.
“Environmental Claim” means any Action, Governmental Order, lien, fine, penalty, or, as to each, any settlement or judgment arising therefrom, by or from any Person alleging liability of whatever kind or nature (including liability or responsibility for the costs of enforcement proceedings, investigations, cleanup, governmental response, removal or remediation, natural resources damages, property damages, personal injuries, medical monitoring, penalties, contribution, indemnification and injunctive relief) arising out of, based on or resulting from any actual or alleged non-compliance with any Environmental Law.
“Environmental Law” means any applicable Law, and any Governmental Order or binding agreement with any Governmental Authority: (a) relating to pollution (or the cleanup thereof) or the protection of natural resources, endangered or threatened species, or the environment (including ambient or indoor air, soil, surface water or groundwater, or subsurface strata); (b) concerning the presence of, exposure to, or the management, manufacture, use, containment, storage, recycling, reclamation, reuse, treatment, generation, discharge, transport, processing, production, disposal or remediation of any Hazardous Materials; and (c) occupational health and safety, industrial hygiene, indoor air quality, or the protection of human health from workplace exposure to Hazardous Materials, including but not limited to the Occupational Safety and Health Act of 1970 (29 U.S.C. § 651 et seq.), as amended, and any state or local equivalents.
| -3- |
“Environmental Notice” means any written directive, notice of violation or infraction, or notice respecting any Environmental Claim relating to actual or alleged non-compliance with any Environmental Law.
“Environmental Permit” means any Regulatory Authorization, letter, clearance, consent, waiver, closure, exemption, decision, or other action required under or issued, granted, given, authorized by, or made pursuant to Environmental Law.
“ERISA” means the Employee Retirement Income Security Act of 1974, as amended, and the regulations promulgated thereunder.
“ERISA Affiliate” means all employers, trades, or businesses (whether or not incorporated) that would be treated together with Seller or any of its Affiliates as a “single employer” within the meaning of Section 414 of the Code.
“Excepted Losses” has the meaning set forth in Section 8.04(d).
“Exchange Act” has the meaning set forth in Section 5.05.
“Excluded Assets” has the meaning set forth in Section 2.02.
“Excluded Contracts” has the meaning set forth in Section 2.02(b).
“Excluded Liabilities” has the meaning set forth in Section 2.04.
“Expiration Date” has the meaning set forth in Section 8.01.
“Expense Reimbursement” has the meaning set forth in Section 10.01.
“FCPA” has the meaning set forth in Section 4.24(b).
“FDA” means the U.S. Food and Drug Administration and any successor Governmental Authority.
“FDA Milestone” has the meaning set forth in Section 2.10(a)(i).
“Financial Statements” has the meaning set forth in Section 4.04.
“First Commercial Sale” means, on a Product-by-Product and country-by-country basis, the first sale of a given Product by Buyer or any of Buyer’s Affiliates or (sub)licensees to a Third Party in a country following receipt of the applicable Regulatory Authorizations that are necessary for the commercialization of such Product in such country, or, if no such Regulatory Authorizations are required in such country, the first sale of such Product to a Third Party in such country.
“First Sales Milestone” has the meaning set forth in Section 2.10(a)(ii).
| -4- |
“Fraud” means, with respect to a party, common law fraud under the Laws of the State of Delaware with respect to the making of any representation or warranty of such party set forth in this Agreement or in any other Ancillary Document.
“Fundamental Representations” means the representations and warranties of Seller set forth in [***].
“GAAP” means United States generally accepted accounting principles in effect from time to time.
“Generic/Biosimilar” means, with respect to a Product on a Product-by-Product and country-by-country basis, any pharmaceutical or biological product (including any “generic,” “biosimilar,” “biogeneric,” “follow-on biologic,” or “similar biological medicinal product”) that: (a) is approved by the applicable Governmental Authority in such country pursuant to an abbreviated regulatory process in reliance on or in reference to the NDA or biologics license application for such Product held by Buyer or its Affiliates or (sub)licensees (or on the data contained or incorporated by reference therein); (b) is sold in, or commercially available in, such country by a Third Party that is not a sublicensee of Buyer or its Affiliates and did not purchase such product in a fully authorized chain of distribution that included Buyer or any of its Affiliates or (sub)licensees; and (c) either (i) contains an active substance or pharmaceutical ingredient that is highly similar to and has no clinically meaningful differences from the Product, or (ii) is approved as “comparable,” “interchangeable,” “bioequivalent,” “biosimilar,” “generic,” or other similar designation by the applicable Governmental Authority, in each case, in a manner that permits substitution of such product for the Product under Applicable Regulatory Laws in such country.
“Governmental Authority” means any federal, state, local, or foreign government or political subdivision thereof, or any regulatory authority, agency or instrumentality of such government or political subdivision, or any self-regulated organization or other non-governmental regulatory authority or quasi-governmental authority (to the extent that the rules, regulations or orders of such organization or authority have the force of Law), or any arbitrator, court or tribunal of competent jurisdiction.
“Government Official” means any officer, employee, or representative of any Governmental Authority or public international organization, any political party or party official, any candidate for political office, or any person acting in an official capacity for or on behalf of any of the foregoing.
“Governmental Order” means any order, writ, judgment, injunction, decree, stipulation, determination, or award entered by or with any Governmental Authority.
“Hazardous Materials” means (a) any material, substance, chemical, element, waste, product, derivative, compound, mixture, solid, liquid, mineral or gas, in each case, whether naturally occurring or manmade, that is hazardous, acutely hazardous, toxic, a pollutant, a contaminant or words of similar import or regulatory effect under Environmental Laws, or which poses a hazard to human health, safety, or the environment; (b) any petroleum or petroleum-derived products, radon, radioactive materials or wastes, asbestos in any form, lead or lead-containing materials, urea formaldehyde foam insulation, polychlorinated biphenyls, and per- and polyfluoroalkyl substances; (c) any active pharmaceutical ingredients (APIs), excipients, chemical intermediates, starting materials, reagents, research chemicals, or biopharmaceutical products, whether finished, unfinished, or under development; (d) any recombinant DNA, RNA, infectious agents, biological toxins, viruses, bacteria, fungi, prions, cell lines, cultures, or hazardous bloodborne pathogens, regardless of biosafety level (BSL-1 through BSL-4); (e) any substance subject to the Controlled Substances Act or similar international, federal, state, or local drug control or scheduling restrictions; and (f) any biohazardous waste, sharps, radioactive materials, or mixed chemical-radiological wastes generated during research, development, clinical trials, or manufacturing.
| -5- |
“Incidental License” means a Contract entered into in the ordinary course of business where the only rights or licenses to Intellectual Property consist of: (a) non-exclusive licenses granted pursuant to Contracts for the engagement of employees and contractors authorizing the use of Intellectual Property created therein solely for the performance of such person’s duties for Seller, (b) rights to use confidential information for limited purposes pursuant to written obligations of confidentiality, non-disclosure and non-use, (c) non-exclusive licenses of limited duration to end customers for their use of Seller’s products and services substantially in the form of license set forth in Seller’s standard forms of customer agreement that have been made available to Buyer, (d) non-exclusive licenses granted to vendors to use Intellectual Property owned by Seller, solely for the purpose of providing services to Seller, (e) Non-Negotiated Vendor Contracts, (f) licenses to open source software; (g) non-exclusive licenses authorizing the use of feedback and suggestions related solely to a vendor’s products or services, (h) non-exclusive licenses granted to or granted by Seller’s customers and vendors in the ordinary course of business authorizing limited use of brand materials for marketing purposes that do not include a “naked” license, (i) Contracts to purchase or lease equipment or materials, such as a photocopier, computer, or mobile phone that also contains a license of Intellectual Property embedded in such equipment or materials, (j) nondisclosure agreements, (k) material transfer agreements, (l) fee-for-service agreements, (m) research agreements, (n) clinical trial agreements and (o) invention assignment agreements with employees and contractors.
“IND” has the meaning set forth in Section 4.17(d).
“Indemnified Party” has the meaning set forth in Section 8.05.
“Indemnifying Party” has the meaning set forth in Section 8.05.
“Independent Accountant” means an impartial nationally recognized firm of independent certified public accountants, other than Seller’s Accountants or Buyer’s Accountants, appointed by Buyer and Seller by mutual agreement.
“Insurance Policies” has the meaning set forth in Section 4.13.
“Intellectual Property” means any and all rights in, arising out of, or associated with any of the following in any jurisdiction throughout the world: (a) issued patents and patent applications (whether provisional or non-provisional), including divisionals, continuations, continuations-in-part, substitutions, reissues, reexaminations, extensions, or restorations of any of the foregoing, and other Governmental Authority-issued indicia of invention ownership (including certificates of invention, petty patents, and patent utility models) (“Patents”); (b) trademarks, service marks, brands, certification marks, logos, trade dress, trade names, and other similar indicia of source or origin, together with the goodwill connected with the use of and symbolized by, and all registrations, applications for registration, and renewals of, any of the foregoing (“Trademarks”); (c) copyrights and works of authorship, whether or not copyrightable, and all registrations, applications for registration, and renewals of any of the foregoing (“Copyrights”); (d) trade secrets, know-how, formulations, specifications, inventions (whether or not patentable), discoveries, improvements, technology, business and technical information, databases, data compilations and collections, tools, methods, processes, techniques, and other confidential and proprietary information and all rights therein (“Know-how”); (e) mask works, and all registrations, applications for registration, and renewals thereof; (f) industrial designs, and all Patents, registrations, applications for registration, and renewals thereof; (g) internet domain names and social media account or user names (including “handles”), whether or not Trademarks, all associated web addresses, URLs, websites and web pages, social media sites and pages, and all content and data thereon or relating thereto, whether or not Copyrights; (h) computer programs, operating systems, applications, firmware and other code, including all source code, object code, application programming interfaces, data files, databases, protocols, specifications, and other documentation thereof (“Software”); and (i) rights of publicity.
| -6- |
“Intellectual Property Agreements” means all licenses, sublicenses, consent to use agreements, settlements, coexistence agreements, covenants not to sue, standstill agreements, covenants not to challenge or enforce, waivers, releases, permissions, domain name registration agreements, terms of service and other Contracts, whether written or oral, relating to the Intellectual Property Assets to which Seller is a party or a beneficiary or under which Seller or the Intellectual Property Assets are otherwise bound.
“Intellectual Property Assets” means all Intellectual Property that is owned by or licensed to Seller and used or held for use in the conduct of the Business as currently conducted or otherwise related to APT-1011, including any surviving rights to seek revival, restoration, or re-establishment of any such Intellectual Property, together with all claims and causes of action with respect to such Intellectual Property, whether accruing before, on, or after the date hereof, including all rights to and claims for damages, restitution, and injunctive and other legal or equitable relief for past, present, or future infringement, misappropriation, or other violation thereof.
“Intellectual Property Assignments” has the meaning set forth in Section 3.02(a)(ii).
“Intellectual Property Registrations” means all Intellectual Property Assets that are subject to any issuance, registration, or application by or with any Governmental Authority or authorized private registrar in any jurisdiction, including issued Patents, registered Trademarks, domain names and registered Copyrights, and pending applications for any of the foregoing.
“Interim Balance Sheet” has the meaning set forth in Section 4.04.
“Interim Balance Sheet Date” has the meaning set forth in Section 4.04.
“Inventory” has the meaning set forth in Section 2.01(c).
“Know-how” has the meaning set forth in the definition of Intellectual Property.
“Knowledge of Seller” or “Seller’s Knowledge” or any other similar knowledge qualification, means the actual or constructive knowledge of [***] or [***], after due inquiry of personnel reasonably expected to have knowledge of the relevant subject matter.
“Law” means any statute, law, ordinance, regulation, rule, code, order, constitution, treaty, common law, judgment, decree, other requirement, or rule of law of any Governmental Authority.
“Liabilities” means liabilities, obligations, or commitments of any nature whatsoever, asserted or unasserted, known or unknown, absolute, or contingent, accrued or unaccrued, matured or unmatured or otherwise.
“Licensed Intellectual Property” means all Intellectual Property in which Seller holds any rights or interests granted by Third Parties and which is used or held for use in the conduct of the Business as currently conducted (except non-exclusive licenses or sublicenses granted in the ordinary course of business).
“Lockup Release Date” has the meaning set forth in Section 2.11(a).
| -7- |
“Losses” means losses, damages, Liabilities, deficiencies, Actions, judgments, interest, awards, penalties, fines, costs or expenses of whatever kind, including reasonable attorneys’ fees and the cost of enforcing any right to indemnification hereunder and the cost of pursuing any insurance providers; provided, however, that “Losses” shall not include consequential, special, multiple, loss-of-revenue based, lost-profit based or punitive damages, except to the extent actually awarded to a Governmental Authority or other third party.
“Material Adverse Effect” means any event, occurrence, fact, condition or change that has had, or would reasonably be expected to have, individually or in the aggregate, a materially adverse effect that is durationally significant on the Products or the Acquired Assets, taken as a whole; provided, however, that “Material Adverse Effect” shall not include any event, occurrence, fact, condition or change, directly or indirectly, arising out of or attributable to: (i) general economic or political conditions; (ii) conditions generally affecting the orphan-drug, specialty pharmaceutical, allergy or gastroenterology-focused industries in which the Business operates; (iii) any changes in financial or securities markets in general; (iv) acts of war (whether or not declared), armed hostilities or terrorism, or the escalation or worsening thereof; (v) any action required or permitted by this Agreement or taken at Buyer’s written request, or any action taken (or omitted to be taken) with the written consent of or at the written request of Buyer; (vi) any changes in applicable Laws or accounting rules, including GAAP; (vii) the public announcement, pendency or completion of the transactions contemplated by this Agreement, including the impact thereof on relationships with employees, customers, suppliers, vendors, or regulators; (viii) any natural or man-made disasters or acts of God; (ix) any epidemics, pandemics, or disease outbreaks or any worsening thereof; (x) any matter set forth in the Disclosure Schedules; (xi) any change, setback, or delay in the clinical development, regulatory review, or regulatory approval timeline of the Product Candidate, except to the extent resulting from Seller’s breach of this Agreement or any failure by Seller or any Person acting on Seller’s behalf to materially comply with applicable Laws administered or enforced by FDA relating to the Product Candidate; or (xii) any failure by the Business to meet any internal or published projections, forecasts or revenue or earnings predictions (provided that the underlying causes of such failures (subject to the other provisions of this definition) shall not be excluded); provided further, however, that any event, occurrence, fact, condition or change referred to in clauses (i) through (xi) immediately above shall be taken into account in determining whether a Material Adverse Effect has occurred or would reasonably be expected to occur to the extent that such event, occurrence, fact, condition or change has a disproportionate effect on the Products or the Acquired Assets compared to other similarly situated orphan-drug, allergy or specialty gastroenterology product candidates.
“Material Contracts” has the meaning set forth in Section 4.07(a).
“Material Customers” has the meaning set forth in Section 4.12(a).
“Material Suppliers” has the meaning set forth in Section 4.12(b).
“Milestone Event” has the meaning set forth in Section 2.10(a).
“Milestone Payment” has the meaning set forth in Section 2.10(a).
“NDA” has the meaning set forth in Section 4.17(k).
| -8- |
“Net Sales” means the gross amounts invoiced or otherwise received by Buyer, its Affiliates, and (sub)licensees for sales of Products to Third Parties, less only the following deductions, in each case to the extent actually incurred, allowed, paid, or accrued and not otherwise recovered or reimbursed: (a) trade, quantity, and cash discounts, credits, and allowances, including those granted for price adjustments, billing errors, rejected goods, or damaged goods; (b) rebates and chargebacks actually allowed, given, or accrued, including governmental, managed care, and hospital buying group rebates and chargebacks; (c) sales, excise, use, value-added, and similar taxes (but not income taxes) and customs or import duties, in each case to the extent included in the invoiced amount; and (d) actual freight, shipping, handling, and insurance costs, to the extent actually incurred, separately itemized, and not separately invoiced to the Third Party. No particular amount shall be deducted more than once in calculating Net Sales. Net Sales shall be recognized only upon the final sale of Products into the commercial supply chain; provided, that intercompany transfers for resale shall not constitute Net Sales, but the subsequent resale of such Products to a Third Party shall constitute Net Sales. For any sale for non-monetary consideration or that is not an arm’s-length transaction, Net Sales shall be calculated based on the average sales price charged for such Product during the applicable period or, in the absence of such sales, the fair market value of such Product. Net Sales shall be determined from Buyer’s books and records maintained in accordance with GAAP, consistently applied, and Seller shall have the right to audit and verify such books and records in accordance with Section 2.09(f). In the event a Product is sold as part of a Combination Product, Net Sales of such Product, for the purpose of determining Royalties, will be calculated as follows: (i) [***]; and (ii) if the calculation in clause (i) cannot be determined because [***]; provided, that if the parties are unable to agree within [***] after a request by either party, such matter shall be resolved pursuant to the dispute resolution procedures set forth in Section 2.09(f). Buyer and its Affiliates and (sub)licensees shall not sell any Product as part of a Combination Product, or in a bundle with other products, in a manner that disproportionately discounts the selling price of such Product as compared to the weighted-average discount applied to the other products in such Combination Product or bundle, as a percentage of the respective list prices of such Product and such other products.
“Non-Negotiated Vendor Contract” means a Contract that meets all of the following conditions: (i) such Contract grants to Seller a non-exclusive license to download or use generally commercially available, non-customized Software, in object code form only, or a non-exclusive right to access and use the functionality of such Software on a hosted or “software-as-a-service” basis; (ii) the Software licensed or made available under such Contract is not included, incorporated or embedded in, linked to, combined or distributed with the Products; and (iii) the Contract does not require Seller to pay any license fee, subscription fee, service fee or other amount, except for a one-time license fee of no more than $100,000 or ongoing subscription or service fees of no more than $100,000 per year.
“Owned Intellectual Property” means all Intellectual Property owned or purported to be owned by Seller, in whole or in part which is used or held for use in the conduct of the Business.
“Patents” has the meaning set forth in the definition of Intellectual Property.
“Permitted Encumbrances” has the meaning set forth in Section 4.08.
“Person” means an individual, corporation, partnership, joint venture, limited liability company, Governmental Authority, unincorporated organization, trust, association, or other entity.
“Pre-Closing Tax Period” means any taxable period ending on or before the Closing Date and, with respect to any taxable period beginning before and ending after the Closing Date, the portion of such taxable period ending on and including the Closing Date.
“Privacy Laws” has the meaning set forth in Section 4.22(a).
“Product Candidate” means APT-1011.
| -9- |
“Product Records” has the meaning set forth in Section 2.01(e).
“Products” means APT-1011 and any products comprising fluticasone propionate as an active pharmaceutical ingredient (alone or in combination with other active pharmaceutical ingredients) as to all fields, indications, formulations, routes of administration and uses, including use of Products to treat EoE and any future Product indications.
“Pro Rata Percentage” has the meaning set forth in Section 8.08.
“Purchase Price” has the meaning set forth in Section 2.05.
“Recipient Consideration Value” has the meaning set forth in Section 8.08.
“Registration Rights Agreement” has the meaning set forth in Section 3.02(a)(iii).
“Regulatory Authorizations” means all permits, licenses, franchises, approvals, clearances, authorizations, registrations, certificates, variances, investigational new drug applications, orphan drug designations, exemptions, Fast Track designations, any other expedited regulatory designations or statuses, and other regulatory determinations and similar rights submitted to or issued or obtained from any applicable Governmental Authorities including, without limitation, the FDA that are necessary for the research, development, manufacture, processing, import, export, labeling, storage, testing, and distribution of APT-1011; provided that, with respect to FDA, the term also includes authorizations required but not yet obtained for such activities and all orphan drug, Fast Track and other expedited regulatory designations or statuses relating to the Product Candidate, whether or not required.
“Regulatory Exclusivity” means any exclusive marketing rights or data protection conferred by a Governmental Authority with respect to a Product in a country, including new chemical entity exclusivity, orphan drug exclusivity, pediatric exclusivity, or any other regulatory data or marketing exclusivity, other than exclusivity conferred solely by a Valid Claim.
“Release” means any actual or threatened release, spilling, leaking, pumping, pouring, emitting, emptying, discharging, injecting, escaping, leaching, dumping, abandonment, disposing (including the abandonment or discarding of barrels, containers, and other closed receptacles containing any Hazardous Materials), or allowing to escape or migrate into or through the indoor or outdoor environment (including, without limitation, ambient or indoor air, surface water, groundwater, land surface or subsurface strata, or within any building, structure, facility or fixture such as cleanroom flooring, HVAC ductwork, or concrete slabs). For purposes hereof, “Release” includes, without limitation, (i) the discharge or introduction of any active pharmaceutical ingredient (API), endocrine disruptor, or antibiotic into municipal sewage systems, publicly owned treatment works, or surface waters; and (ii) the indoor or outdoor emission, venting, or aerosolization of potent chemical compounds, biological agents, or particulate matter outside of primary containment systems.
“Representative” means, with respect to any Person, any and all general partners, directors, officers, employees, consultants, financial advisors, counsel, accountants, and other agents of such Person.
“Restricted Business” means business relating to any orally disintegrating/dissolving/dispersible tablet (ODT) for the treatment of eosinophilic esophagitis (EoE).
“Restricted Period” has the meaning set forth in Section 6.03(a).
| -10- |
“Royalties” has the meaning set forth in Section 2.09(a).
“Royalty Dispute Notice” has the meaning set forth in Section 2.09(f).
“Royalty Floor” has the meaning set forth in Section 2.09(e).
“Royalty Report” has the meaning set forth in Section 2.09(c).
“Royalty Term” has the meaning set forth in Section 2.09(d).
“Sales Milestones” has the meaning set forth in Section 2.10(a)(iii).
“Sanctioned Party” has the meaning set forth in Section 4.24(a).
“Sanctions” has the meaning set forth in Section 4.24(a).
“SEC” has the meaning set forth in Section 5.05.
“SEC Reports” means (a) Buyer’s most recently filed Annual Report on Form 10-K and (b) all Quarterly Reports on Form 10-Q or Current Reports on Form 8-K filed or furnished (as applicable) by Buyer following the end of the most recent fiscal year for which an Annual Report on Form 10-K has been filed and prior to the execution of this Agreement, together in each case with any documents incorporated by reference therein or exhibits thereto.
“Securities Act” means the Securities Act of 1933, as amended.
“Seller” has the meaning set forth in the preamble.
“Seller Indemnitees” has the meaning set forth in Section 8.03.
“Seller’s Accountants” means Hawthorne & Pine, LLC.
“Software” has the meaning set forth in the definition of Intellectual Property.
“Taxes” means all federal, state, local, foreign and other income, gross receipts, sales, use, production, ad valorem, transfer, documentary, franchise, registration, profits, license, lease, service, service use, withholding, payroll, employment, unemployment, estimated, excise, severance, environmental, stamp, occupation, premium, property (real or personal), real property gains, windfall profits, customs, duties or other taxes, fees, assessments or charges of any kind whatsoever, together with any interest, additions or penalties with respect thereto and any interest in respect of such additions or penalties.
“Tax Return” means any return, declaration, report, claim for refund, information return or statement or other document relating to Taxes, including any schedule or attachment thereto, and including any amendment thereof.
“Territory” means all countries and territories worldwide.
“Third Party” means any Person other than Seller, Buyer, and their respective Affiliates.
“Third-Party Claim” has the meaning set forth in Section 8.05(a).
| -11- |
“Trademarks” has the meaning set forth in the definition of Intellectual Property.
“Upfront Shares” has the meaning set forth in Section 2.05.
“Valid Claim” means (a) a claim of an issued and unexpired Patent included in the Intellectual Property Assets that is in force in the applicable country and that has not been revoked, cancelled, withdrawn, abandoned or held unenforceable, unpatentable or invalid by a decision of a court or governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and that has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination, disclaimer or otherwise; or (b) a claim of a pending patent application included in the Intellectual Property Assets that has been filed and is being prosecuted in good faith and has not been abandoned, finally rejected, or otherwise finally disposed of without a pending appeal or a timely available right to appeal; provided that such pending application has not been pending for more than seven years after the earliest priority date for such application.
“VWAP” means the volume weighted average price of the Abeona Common Stock, as reported on the Nasdaq Capital Market, for the applicable period.
“WARN Act” means the federal Worker Adjustment and Retraining Notification Act of 1988, and similar state, local and foreign laws related to plant closings, relocations, mass layoffs, and employment losses.
ARTICLE II
Purchase and Sale
Section 2.01 Purchase and Sale of Assets. Subject to the terms and conditions set forth herein, at the Closing, Seller shall sell, assign, transfer, convey and deliver to Buyer, and Buyer shall purchase from Seller, free and clear of any Encumbrances other than Permitted Encumbrances, all of Seller’s right, title and interest in, to, and under the following assets, properties, and rights, whether tangible or intangible (including goodwill), wherever located and whether now existing or hereafter acquired, in each case to the extent relating to the Products or used or held for use in connection with the Business (other than the Excluded Assets) (collectively, the “Acquired Assets”):
(a) all worldwide rights to the Products;
(b) all Intellectual Property Assets;
(c) all inventory, finished goods, raw materials, work in progress, packaging, supplies, components, and other inventories relating to the Products (“Inventory”);
(d) (i) all Regulatory Authorizations which are held by Seller and required for the conduct of the Business as currently conducted or for the ownership and use of the Acquired Assets and the Products, including, without limitation, those listed in Section 4.17 of the Disclosure Schedules and (ii) all regulatory and sponsorship files and materials relating to the Products, including without limitation all applications, submissions, complete and unredacted FDA and other regulatory authority correspondence, meeting requests, briefing books, minutes, and written responses concerning, without limitation, the confirmatory study, endpoint strategy, and sufficiency of the confirmatory Phase 3 study to support Product approval, and all designations, approvals, and files from all jurisdictions worldwide, including the U.S. IND and orphan drug designation and all of Seller’s transferable rights under or with respect to any drug master file, letter of authorization, or other right of reference relating to the Products;
| -12- |
(e) all data and records relating to the Products including, without limitation, all clinical, nonclinical, pharmacovigilance, biostatistical and chemistry, manufacturing, and controls (“CMC”) data, databases, reports, samples, complete data and documentation from the FLUTE 1, FLUTE 2, and FLUTE 3 studies, and the confirmatory Phase 3 study, reference standards, regulatory materials and correspondence, manufacturing and quality records, research and development files and records, and files relating to the Intellectual Property Assets and the Intellectual Property Agreements (“Product Records”);
(f) all Contracts, including Intellectual Property Agreements, relating to APT-1011, including manufacturing, supply, and distribution agreements, set forth on Section 2.01(f) of the Disclosure Schedules (the “Assigned Contracts”);
(g) all rights to any Actions of any nature available to or being pursued by Seller to the extent related to the Business, the Acquired Assets, or the Assumed Liabilities, whether arising by way of counterclaim or otherwise (other than any claims relating to Tax matters for a Pre-Closing Tax Period);
(h) all prepaid expenses, credits, advance payments, claims, security, refunds, rights of recovery, rights of set-off, rights of recoupment, deposits, charges, sums, and fees, in each case to the extent relating to the Acquired Assets (including any such item relating to the payment of Taxes on the Acquired Assets);
(i) all of Seller’s rights under warranties, indemnities, and all similar rights against third parties to the extent related to any Acquired Assets;
(j) all insurance benefits, including rights and proceeds, arising from or relating to the Acquired Assets, or the Assumed Liabilities; and
(k) all goodwill relating to the Business and the Products.
Section 2.02 Excluded Assets. Notwithstanding the foregoing, the Acquired Assets shall not include the following assets (collectively, the “Excluded Assets”):
(a) cash, cash equivalents, and all accounts or notes receivable held by Seller, and any security, claim, remedy or other right related to any of the foregoing, in each case existing as of the Closing;
(b) any Contracts (including Intellectual Property Agreements) that are not Assigned Contracts (the “Excluded Contracts”);
(c) Intellectual Property or data of Seller not included in the Acquired Assets;
(d) the corporate books and records, organizational documents, stock records, Tax Returns, books of account or other records having to do with the corporate organization of Seller, and all documents protected by attorney-client privilege or other applicable legal privilege (other than such documents to the extent relating to the Business or the Products and reasonably necessary for Buyer’s ownership and exploitation of the Acquired Assets, of which Buyer will be provided copies);
(e) all Benefit Plans and assets attributable thereto;
| -13- |
(f) all insurance policies of Seller and rights thereunder, other than rights to proceeds relating to the Acquired Assets or the Assumed Liabilities;
(g) any claims, refunds, credits, causes of action, rights of recovery and rights of set-off of any kind relating to any Excluded Asset or Excluded Liability;
(h) the assets, properties and rights specifically set forth on Section 2.02(h) of the Disclosure Schedules;
(i) all Tax assets; and
(j) the rights which accrue or will accrue to Seller under this Agreement and the Ancillary Documents.
Section 2.03 Assumed Liabilities. Subject to the terms and conditions set forth herein, Buyer shall assume and agree to pay, perform and discharge only the following Liabilities of Seller (collectively, the “Assumed Liabilities”), and no other Liabilities:
(a) all Liabilities arising after the Closing under the Assigned Contracts, but only to the extent that such Liabilities thereunder are required to be performed after the Closing Date and do not relate to any failure to perform, improper performance, warranty, or other breach, default, or violation by Seller on or prior to the Closing;
(b) all Liabilities relating to or arising from the Acquired Assets or the Products, in each case to the extent accruing or arising solely from events occurring after the Closing, including Buyer’s ownership, development, manufacture, and commercialization of the Products after the Closing;
(c) fifty percent (50%) of any sales, use, transfer, documentary, stamp, registration, value added, or other similar Taxes and fees (including any penalties and interest) incurred in connection with the transfer of the Acquired Assets pursuant to this Agreement, as set forth in Section 6.08; and
(d) those Liabilities of Seller set forth on Section 2.03(d) of the Disclosure Schedules.
Section 2.04 Excluded Liabilities. Notwithstanding the provisions of Section 2.03 or any other provision in this Agreement to the contrary, Buyer shall not assume and shall not be responsible to pay, perform, or discharge any Liabilities of Seller or any of its Affiliates of any kind or nature whatsoever other than the Assumed Liabilities (the “Excluded Liabilities”). Seller shall, and shall cause each of its Affiliates to, pay and satisfy in due course all Excluded Liabilities which they are obligated to pay and satisfy. Without limiting the generality of the foregoing, the Excluded Liabilities shall include, but not be limited to, the following:
(a) any Liability arising out of or relating to the Products, the Acquired Assets, or the Business to the extent arising from facts, circumstances, or events occurring, or Products manufactured or sold, prior to Closing, including, without limitation, (i) any product liability or similar claim for injury to a Person or property which arises out of or is based upon any express or implied representation, warranty, agreement, or guaranty made by Seller, or by reason of the improper performance or malfunctioning of any products manufactured or sold by Seller (including the Products), improper design or manufacture, failure to adequately package, label, or warn of hazards or other related product defects of any products manufactured or sold by Seller (including the Products) or any service performed by Seller; and (ii) any recall, design defect or similar claims of any products manufactured or sold (including the Products) or any service performed by Seller;
| -14- |
(b) any Liabilities associated with debt, loans, credit facilities, or other indebtedness of Seller and/or the Business owing to financial institutions or any other third party;
(c) any trade accounts payable of Seller of any kind, whether or not accounted for on the Interim Balance Sheet, including any which constitute intercompany payables owing to Affiliates of Seller;
(d) any Liability for (i) Taxes of Seller (or any partner or Affiliate of Seller) or relating to the Business, the Acquired Assets, or the Assumed Liabilities for any Pre-Closing Tax Period; (ii) except for Buyer’s 50% share of transfer Taxes that constitutes an Assumed Liability under Section 2.03(c), Taxes of Seller that arise out of the consummation of the transactions contemplated hereby or that are the responsibility of Seller pursuant to Section 6.08; or (iii) other Taxes of Seller (or any partner or Affiliate of Seller) of any kind or description (including any Liability for Taxes of Seller (or any partner or Affiliate of Seller) that becomes a Liability of Buyer under any common law doctrine of de facto merger or transferee or successor liability or otherwise by operation of contract or Law);
(e) any Liabilities of Seller for any present or former employees, officers, directors, retirees, independent contractors or consultants of Seller, including, without limitation, any Liabilities associated with any claims for compensation, wages, or other benefits, bonuses, accrued vacation, workers’ compensation, severance, retention, termination, or other payments or any Liability arising under or in connection with any Benefit Plan providing benefits to any present or former employee of Seller, but excluding any such Liabilities to the extent that they arise from Buyer’s acts or omissions after the Closing;
(f) any Liabilities arising out of, in respect of, or in connection with the failure by Seller or any of its Affiliates to comply with any Law or Governmental Order including, without limitation, any Environmental Claims or Liabilities under Environmental Laws, in each case, to the extent arising out of or relating to facts, circumstances or conditions existing on or prior to the Closing or otherwise to the extent arising out of any actions or omissions of Seller occurring on or prior to the Closing;
(g) any Liabilities relating to or arising out of any Excluded Asset;
(h) any Liabilities in respect of any pending or threatened Action arising out of, relating to, or otherwise in respect of facts or circumstances (including, without limitation, the operation of the Business or the Acquired Assets) existing as of the Closing;
(i) any Liabilities to indemnify, reimburse or advance amounts to any present or former general partner, limited partner, officer, director, employee, representative, or agent of Seller (including with respect to any breach of fiduciary obligations by same), except for indemnification of same pursuant to Section 8.03 as Seller Indemnitees;
(j) any Liabilities under (i) the Excluded Contracts or (ii) any other Contracts, including Intellectual Property Agreements, to the extent such Liabilities arise out of or relate to a breach by Seller of such Contracts prior to Closing;
(k) any Liabilities of the Business relating to or arising from unfulfilled commitments, quotations, purchase orders, customer orders or work orders that (i) do not constitute part of the Acquired Assets issued by the Business’s customers to Seller on or before the Closing; (ii) did not arise in the ordinary course of business; or (iii) are not validly and effectively assigned to Buyer pursuant to this Agreement; and
| -15- |
(l) any Liabilities of Seller arising or incurred in connection with the negotiation, preparation, investigation and performance of this Agreement, the Ancillary Documents and the transactions contemplated hereby and thereby, including, without limitation, fees and expenses of counsel, accountants, consultants, advisers, and others; provided, for the avoidance of doubt, that this clause (l) shall not affect the Expense Reimbursement.
Section 2.05 Purchase Price. In addition to the Royalties and Milestone Payments described in Section 2.09 and Section 2.10, respectively, and the assumption of the Assumed Liabilities, as consideration for the Acquired Assets (collectively, the “Purchase Price”), at the Closing, Buyer will issue to Seller $20,000,000 in value of Abeona Common Stock (the “Upfront Shares”), subject to set-off pursuant to Article VIII. The number of Upfront Shares to be issued to Seller will be based on the 20-trading-day VWAP of Abeona Common Stock ending on the trading day immediately before the Closing Date (the “Closing Stock Price”), subject to compliance with the rules of the Nasdaq Capital Market. If, during the period between the date of this Agreement and the Closing Date, the outstanding shares of Abeona Common Stock shall have been changed into, or exchanged for, a different number or class of shares by reason of any stock split, reverse stock split, stock dividend, subdivision, reclassification, recapitalization, combination, exchange of shares or other similar transaction, the number of Upfront Shares issuable pursuant to this Section 2.05 shall be equitably adjusted to eliminate the effects of such event, so as to provide Seller the same economic value as contemplated by this Section 2.05 prior to such event. Except for the Upfront Shares, the Royalties, the Milestone Payments (to the extent achieved) and the Expense Reimbursement, no other payment or consideration shall be due to Seller under this Agreement.
Section 2.06 Allocation of Purchase Price. Seller and Buyer agree that the Purchase Price and the Assumed Liabilities (plus other relevant items) shall be allocated among the Acquired Assets for all purposes (including Tax and financial accounting) in accordance with Section 1060 of the Code and as shown on the allocation schedule (the “Allocation Schedule”). A draft of the Allocation Schedule shall be prepared by Seller and delivered to Buyer [***] after the Closing Date. If Buyer notifies Seller in writing that Buyer objects to one or more items reflected in the Allocation Schedule, Seller and Buyer shall negotiate in good faith to resolve such dispute; provided, however, that if Seller and Buyer are unable to resolve any dispute with respect to the Allocation Schedule within [***] following the Closing Date, such dispute shall be resolved by the Independent Accountant. The fees and expenses of such accounting firm shall be borne equally by Seller and Buyer. Buyer and Seller shall file all Tax Returns (including IRS Form 8594 and any amended returns and claims for refund) and information reports in a manner consistent with the Allocation Schedule and will not take any position inconsistent therewith except as required by a final determination of a taxing authority. No portion of the Purchase Price and the Assumed Liabilities shall be separate consideration for, or allocable to, any restrictive covenant of Seller hereunder.
Section 2.07 Withholding Tax. Buyer shall be entitled to deduct and withhold from the Purchase Price all Taxes that Buyer may be required to deduct and withhold under any provision of applicable Law relating to Taxes. Buyer shall use commercially reasonable efforts to notify Seller in advance of any proposed Tax withholding and will consider in good faith whether the amount of withholding Tax may be reduced through the delivery of a certificate or by other means. All such withheld amounts shall be treated as delivered to Seller hereunder.
| -16- |
Section 2.08 Third Party Consents. To the extent that Seller’s rights under any Contract or Regulatory Authorization constituting an Acquired Asset, or any other Acquired Asset, may not be assigned to Buyer without the consent of another Person which has not been obtained, this Agreement shall not constitute an agreement to assign the same if an attempted assignment would constitute a breach thereof or be unlawful, and Seller, at its expense, shall use Commercially Reasonable Efforts to obtain any such required consent(s) as promptly as possible. If any such consent shall not be obtained or if any attempted assignment would be ineffective or would impair Buyer’s rights under the Acquired Asset in question so that Buyer would not in effect acquire the benefit of all such rights, Seller, to the maximum extent permitted by Law and the Acquired Asset, shall act after the Closing as Buyer’s agent in order to obtain for it the benefits thereunder and shall cooperate, to the maximum extent permitted by Law and the Acquired Asset, with Buyer in any other reasonable arrangement designed to provide such benefits to Buyer.
Section 2.09 Royalties.
(a) As additional consideration for the Acquired Assets, during the applicable Royalty Term, Buyer shall pay to Seller royalties (“Royalties”) on annual worldwide Net Sales of Products, calculated on a country-by-country and Product-by-Product basis for each calendar year, as follows:
(i) [***] percent ([***]%) on the portion of annual worldwide Net Sales up to and including $[***];
(ii) [***] percent ([***]%) on the portion of annual worldwide Net Sales above $[***] up to and including $[***]; and
(iii) [***] percent ([***]%) on the portion of annual worldwide Net Sales above $[***].
(b) No Royalty shall be payable with respect to (i) free samples or free goods; (ii) compassionate-use or named-patient supply provided at or below cost; (iii) supply for use in clinical trials; (iv) intercompany transfers between Buyer and its Affiliates that do not result in a sale to a Third Party; or (v) bona fide donations of Product.
(c) Buyer shall pay all Royalties owed for (i) the first three calendar quarters of each year within [***] after the end of such calendar quarter, and (ii) the final calendar quarter of each year within [***] after the end of such calendar year, and, in each case, shall provide Seller with a report setting forth, on a Product-by-Product and country-by-country basis, Net Sales for such quarter (including an itemized breakdown of all deductions and reductions taken from gross sales in calculating such Net Sales) and the calculation of the Royalties payable thereon (each, a “Royalty Report”). Royalties shall be paid in Dollars by wire transfer of immediately available funds to the account designated in writing by Seller.
(d) Royalties shall be payable, on a country-by-country and Product-by-Product basis, from the Closing Date until the latest of: (i) expiration of the last Valid Claim covering such Product in such country; (ii) expiration of Regulatory Exclusivity for such Product in such country; or (iii) the seventh (7th) anniversary of the date of First Commercial Sale of such Product in such country (as to each Product and country, the “Royalty Term”). Upon expiration of the Royalty Term for a Product in a country no further Royalties shall be due with respect to such country.
(e) The Royalty rates set forth in Section 2.09(a) shall be subject to reduction as follows: (i) following the first arm’s-length sale in a country of a Generic/Biosimilar of a Product by a Third Party not authorized by Buyer, its Affiliates or (sub)licensees, upon Net Sales of such Product in such country falling below 50% of the Net Sales of such Product in such country for the corresponding period immediately prior to such Generic/Biosimilar entry, the Royalty rate applicable to Net Sales of such Product in such country shall be reduced by 50%; and (ii) if Buyer or its Affiliate is required to pay a Third Party royalty under a license to Patents that are necessary to make, use or sell APT-1011, Buyer may credit up to 50% of such Third Party royalty payments actually paid against the Royalties otherwise payable to Seller with respect to such Product; provided, that in no event shall the Royalty rate payable to Seller with respect to any Product in any country, after giving effect to the reductions in clauses (i) and (ii), be reduced below 50% of the Royalty amount otherwise payable with respect to such Product in such country (the “Royalty Floor”), it being understood that the Royalty Floor does not entitle Seller to any minimum payment irrespective of the level of Net Sales.
| -17- |
(f) Buyer shall keep, and shall cause its Affiliates and (sub)licensees to keep, complete and accurate books and records in sufficient detail to permit Seller to confirm the accuracy of the figures set forth in each Royalty Report, which shall include a reasonable amount of supporting detail for the calculation of Net Sales and Royalties. Seller shall have [***] following receipt of a Royalty Report to notify Buyer in writing of any dispute as to the calculation of Royalties set forth therein, which notice shall set forth in reasonable detail the basis for such dispute (a “Royalty Dispute Notice”). If Seller does not deliver a Royalty Dispute Notice within such [***] period, such Royalty Report shall be deemed final, conclusive, and binding on the parties. If Seller timely delivers a Royalty Dispute Notice, Buyer and Seller shall cooperate in good faith to resolve the disputed items as promptly as possible. If Buyer and Seller are unable to resolve such dispute within [***] (or such longer period as Buyer and Seller mutually agree in writing) after Buyer’s receipt of the Royalty Dispute Notice, either party may refer the dispute to the Independent Accountant for resolution. The Independent Accountant shall act only as an expert and not as an arbitrator, shall decide only the specific items in dispute, and its decision as to each such item must be within the range of values proposed by Buyer and Seller, respectively, with the Independent Accountant’s review limited to whether the disputed calculation was prepared in accordance with this Agreement or contains mathematical errors. Buyer and Seller shall each provide the Independent Accountant with such information as it reasonably requests and shall otherwise cooperate in good faith to facilitate its review, which the Independent Accountant shall use commercially reasonable efforts to complete within [***] of its engagement. The Independent Accountant’s determination shall be final, conclusive, and binding on the parties, absent fraud or manifest error. The fees and expenses of the Independent Accountant shall be borne by Buyer, on the one hand, and Seller, on the other hand, based on the percentage that the portion of the contested amount not awarded to each party bears to the amount actually contested by such party. If the dispute resolution process set forth in this Section 2.09(f) reveals an underpayment, Buyer shall pay the amount of such underpayment together with interest as provided in Section 8.06(a), and if the underpayment exceeds five percent (5%) of the Royalties actually paid for the period in dispute, Buyer shall bear the reasonable fees and expenses of the Independent Accountant without regard to the cost-allocation mechanism set forth above.
Section 2.10 Milestone Payments.
(a) As additional consideration for the Acquired Assets, Buyer shall pay to Seller the following one-time additional amounts (each a “Milestone Payment”) upon the achievement by or on behalf of Buyer of the following events (each, a “Milestone Event”):
(i) $30,000,000 upon the first FDA approval of an NDA for the Product (the “FDA Milestone”);
(ii) $[***] upon the achievement of $[***] in cumulative Net Sales of Product (excluding sales for use as samples, for compassionate-use, or for clinical use) (the “First Sales Milestone”); and
| -18- |
(iii) $[***] upon the achievement of $[***] in cumulative Net Sales of Product (excluding sales for use as samples, for compassionate-use, or for clinical use) (together with the First Sales Milestone, the “Sales Milestones”).
(b) Buyer shall promptly (and in any event no more than [***] after achievement of the FDA Milestone or the closing of Buyer’s books for the quarter in which achievement of any Sales Milestone occurs) notify Seller after a Milestone Event has been achieved. Buyer shall pay or cause to be paid the corresponding Milestone Payment in cash by wire transfer of immediately available funds to the bank account for Seller set forth on Schedule 2.10(b) within (i) [***] of notification by Buyer to Seller of achievement of the FDA Milestone, and (ii) [***] of notification by Buyer to Seller of the realization of each Sales Milestone.
(c) Within [***] following the end of each month of June and each calendar year until the FDA Milestone is achieved or this Agreement is no longer capable of giving rise to achievement of the FDA Milestone, Buyer shall provide Seller with a written update, in reasonable detail, describing Buyer’s progress during the prior six-month period toward the achievement of the FDA Milestone, including a reasonably detailed summary of development, regulatory, and commercialization activities undertaken with respect to the Product during such period.
(d) Within [***] following the end of each calendar year until each Sales Milestone is achieved or this Agreement is no longer capable of giving rise to achievement of any Sales Milestone, Buyer shall provide to Seller a written statement of the cumulative Net Sales through the end of the preceding year. Buyer shall keep, and shall cause its Affiliates and (sub)licensees to keep, complete and accurate books and records in sufficient detail to permit Seller to confirm the achievement of the Milestone Events and the accuracy of the calculation of any Net Sales thresholds applicable thereto. Seller’s review of, and any dispute regarding, such statement shall be governed by the review and dispute resolution process set forth in Section 2.09(f), applied mutatis mutandis, except that the subject of Seller’s review and any resulting dispute shall be the achievement of the Sales Milestones and the calculation of the related Net Sales thresholds rather than the calculation of Royalties. If such process reveals that a Sales Milestone was achieved and the corresponding Milestone Payment was not paid when due, Buyer shall pay the amount of such Milestone Payment together with interest as provided in Section 8.06(a), and Buyer shall bear the reasonable fees and expenses of the Independent Accountant in the manner provided in Section 2.09(f).
(e) Subject to the terms of this Agreement, subsequent to the Closing, Buyer will have the sole discretion, right, and responsibility with regard to all matters relating to the operation of the Business and to determine strategy relating to the Products including, without limitation, branding, pricing, reimbursement, distribution, medical affairs, and commercialization strategy. Buyer will use Commercially Reasonable Efforts to achieve the Milestone Events and to commercialize at least one Product in the United States, and Buyer will not take any action or omit to act with the intent to avoid, prevent, impair, or frustrate the achievement of any Milestone Event; provided that, achievement of any specific particular Net Sales level shall not be required and Buyer makes no guarantee or representation that any Milestone Event will be achieved.
(f) Buyer shall have the right to withhold and set off against any amount otherwise due to be paid pursuant to this Section 2.10 the amount of any Losses to which any Buyer Indemnitee becomes entitled under Article VIII of this Agreement.
(g) The parties hereto understand and agree that (i) the contingent rights to receive any Milestone Payment shall not be represented by any form of certificate or other instrument, are not transferable, except by operation of Laws relating to descent and distribution, divorce and community property, and do not constitute an equity or ownership interest in Buyer, (ii) Seller shall not have any rights as a securityholder of Buyer as a result of Seller’s contingent right to receive any Milestone Payment hereunder, and (iii) no interest is payable with respect to any Milestone Payment.
| -19- |
(h) The parties intend that the contingent rights to receive Royalties and Milestone Payments pursuant to Section 2.09 and Section 2.10 constitute additional purchase price for the Acquired Assets and shall report such payments for Tax purposes consistently with this characterization, unless otherwise required by a change in Law or an adverse determination resulting from a Tax contest.
(i) Buyer shall, as a condition to the sale of all or any material portion of the Business, by asset sale, merger or otherwise, require the acquirer in such transaction to agree to assume the obligations set forth in Section 2.09 and this Section 2.10. For the avoidance of doubt, nothing in this Section 2.10(i) shall require Buyer to obligate an acquirer of Buyer’s assets unrelated to the Business (provided no portion of the Business or Acquired Assets are transferred to such acquiror) to assume the foregoing obligations.
Section 2.11 Lockup; Registration Rights.
(a) The Upfront Shares shall be subject to a staggered lock-up, pursuant to which Seller shall not, directly or indirectly, sell, transfer, pledge, hedge, lend, engage in any short sale with respect to, encumber, or otherwise dispose of any Upfront Shares other than the Closing Shares, except that one-third (1/3) of the Upfront Shares shall be released from the restrictions of this Section 2.11(a) on each of the six (6)-month, twelve (12)-month, and eighteen (18)-month anniversaries of the Closing Date (each such date, a “Lockup Release Date”). Notwithstanding the foregoing, the number of Upfront Shares released from the foregoing restrictions on the first Lockup Release Date (but not the second or third Lockup Release Dates) shall be reduced by the number of Closing Shares. From and after the applicable Lockup Release Date, sales of the portion of the Upfront Shares other than the Closing Shares released from such restrictions on that date shall remain subject to applicable securities Laws, Buyer’s insider trading policies (as in effect from time to time), and any blackout periods applicable to Seller as a recipient of material nonpublic information. A number of Upfront Shares equal to $1,500,000 divided by the Closing Stock Price (the “Closing Shares”) shall not be subject to any lockup but shall remain subject to applicable securities Laws.
(b) Buyer shall provide Seller with customary demand and/or piggyback registration rights with respect to the Upfront Shares, to be set forth in the Registration Rights Agreement to be entered into by Buyer and Seller at the Closing in the form of Exhibit A attached hereto.
(c) Notwithstanding the restrictions set forth in Section 2.11(a), Seller may distribute Upfront Shares, proceeds from the sale or other disposition thereof, and Milestone Payments actually received by Seller to its partners, members, stockholders or other equityholders, and any such recipient may make subsequent distributions of such shares, proceeds or payments to its partners, members, stockholders, beneficiaries or other equityholders (each recipient at any tier, a “Distribution Recipient”, and each such distribution, a “Distribution”). As a condition precedent to each Distribution, Seller shall obtain from each Distribution Recipient and deliver to Buyer a joinder substantially in the form attached as Exhibit B (a “Distribution Joinder”), together with a statement identifying the recipient, its notice details, the shares and other amounts distributed, the portion of the original Upfront Shares represented thereby, its Pro Rata Percentage and its Recipient Consideration Value (each as defined below), with reasonable supporting calculations. Each Distribution Recipient shall comply with the same requirements before making any subsequent Distribution. A recipient that has already executed a Distribution Joinder may instead execute and deliver an updated distribution schedule acknowledging the additional Distribution and resulting limits.
| -20- |
ARTICLE III
Closing
Section 3.01 Closing. Subject to the terms and conditions of this Agreement, the consummation of the transactions contemplated by this Agreement (the “Closing”) shall take place remotely by electronic exchange of documents and signatures, at 10:00 a.m., Eastern time, on the date hereof, or at such other time, date or place as Seller and Buyer may mutually agree. The date on which the Closing is to occur is herein referred to as the “Closing Date”.
Section 3.02 Closing Deliverables.
(a) Concurrently herewith, Seller has delivered to Buyer the following:
(i) a bill of sale and assignment and assumption agreement in the form agreed by the parties (the “Bill of Sale”) and duly executed by Seller, transferring the tangible personal property included in the Acquired Assets to Buyer and effecting the assignment to and assumption by Buyer of the Acquired Assets and the Assumed Liabilities;
(ii) an assignment in the form agreed by the parties (the “Intellectual Property Assignments”) and duly executed by Seller, transferring all of Seller’s right, title, and interest in and to the Intellectual Property Assets to Buyer;
(iii) the Registration Rights Agreement in the form attached as Exhibit A (the “Registration Rights Agreement”) and duly executed by Seller;
(iv) an IRS Form W-9, duly executed by an officer of Seller; and
(v) a certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Seller certifying (i) that attached thereto are true and complete copies of all resolutions adopted by the board of directors or other governing body of Seller authorizing the execution, delivery and performance of this Agreement and the Ancillary Documents to which it is a party and the consummation of the transactions contemplated hereby and thereby, and that all such resolutions are in full force and effect and are all the resolutions adopted in connection with the transactions contemplated hereby and thereby, and (ii) the names and signatures of the officers of Seller authorized to sign this Agreement, the Ancillary Documents, and the other documents to be delivered hereunder and thereunder.
(b) Concurrently herewith, Buyer has delivered to Seller the following:
(i) the Bill of Sale duly executed by Buyer;
(ii) the Upfront Shares by instructing its transfer agent to issue such Upfront Shares in electronic form via book-entry registration in the name of Seller on the books and records of Buyer, and delivering a confirmation or statement of issuance from the transfer agent evidencing such book-entry position to Seller as of the Closing Date;
(iii) the Registration Rights Agreement duly executed by Buyer; and
| -21- |
(iv) a certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Buyer certifying that attached thereto are true and complete copies of all resolutions adopted by the board of directors or other governing body of Buyer authorizing the execution, delivery and performance of this Agreement and the Ancillary Documents to which it is a party and the consummation of the transactions contemplated hereby and thereby, and that all such resolutions are in full force and effect and are all the resolutions adopted in connection with the transactions contemplated hereby and thereby.
ARTICLE IV
Representations and warranties of seller
Except as set forth in the correspondingly numbered Section of the Disclosure Schedules, Seller represents and warrants to Buyer that the statements contained in this Article IV are true and correct as of the date hereof.
Section 4.01 Organization and Qualification of Seller. Seller is a limited partnership duly organized, validly existing and in good standing under the Laws of the state of Delaware and has full limited partnership power and authority to own, operate, or lease the properties and assets now owned, operated, or leased by it and to carry on the Business as currently conducted. Section 4.01 of the Disclosure Schedules sets forth each jurisdiction in which Seller is licensed or qualified to do business, and Seller is duly licensed or qualified to do business and is in good standing in each jurisdiction in which the ownership of the Acquired Assets or the operation of the Business as currently conducted makes such licensing or qualification necessary.
Section 4.02 Authority of Seller. Seller has full limited partnership power and authority to enter into this Agreement and the Ancillary Documents to which Seller is or will be a party, to carry out its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. The execution and delivery by Seller of this Agreement and any Ancillary Document to which Seller is or will be a party, the performance by Seller of its obligations hereunder and thereunder and the consummation by Seller of the transactions contemplated hereby and thereby have been duly authorized by all requisite limited partnership action on the part of Seller. This Agreement has been duly executed and delivered by Seller, and (assuming due authorization, execution and delivery by Buyer) this Agreement constitutes a legal, valid and binding obligation of Seller enforceable against Seller in accordance with its terms, except as may be limited by any bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other similar laws affecting the enforcement of creditors’ rights generally or by general principles of equity. When each Ancillary Document to which Seller is or will be a party has been duly executed and delivered by Seller (assuming due authorization, execution and delivery by each other party thereto), such Ancillary Document will constitute a legal and binding obligation of Seller enforceable against it in accordance with its terms, except as may be limited by any bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other similar laws affecting the enforcement of creditors’ rights generally or by general principles of equity.
| -22- |
Section 4.03 No Conflicts; Consents. The execution, delivery and performance by Seller of this Agreement and the Ancillary Documents to which it is a party, and the consummation of the transactions contemplated hereby and thereby, do not and will not: (a) conflict with or result in a violation or breach of, or default under, any provision of the certificate of limited partnership, limited partnership agreement, or other organizational documents of Seller; (b) conflict with or result in a violation or breach of any provision of any Law or Governmental Order applicable to Seller, the Business or the Acquired Assets; (c) require the consent, notice or other action by any Person under, conflict with, result in a violation or breach of, constitute a default or an event that, with or without notice or lapse of time or both, would constitute a default under, result in the acceleration of or create in any party the right to accelerate, terminate, modify or cancel any Assigned Contract or Regulatory Authorization to which Seller is a party or by which Seller or the Business is bound or to which any of the Acquired Assets are subject; (d) result in the creation or imposition of any Encumbrance other than Permitted Encumbrances on the Acquired Assets; or (e) result in the revocation, suspension, modification, or termination of any Regulatory Authorizations, IND, orphan drug designation, or Fast Track designation held by Seller, whether under applicable Laws or under the terms of any Contract between Seller and a Governmental Authority or Third Party. No consent, approval, Regulatory Authorization, Governmental Order, declaration or filing with, or notice to, any Governmental Authority is required by or with respect to Seller in connection with the execution and delivery of this Agreement or any of the Ancillary Documents to which Seller is or will be a party and the consummation of the transactions contemplated hereby and thereby.
Section 4.04 Financial Statements. Complete copies of the unaudited financial statements consisting of the balance sheet of the Business as at December 31, 2025 and the related statements of income, partners’ capital and cash flow for the year then ended, and unaudited financial statements consisting of the balance sheet of the Business as at June 30, 2026 and the related statements of income and retained earnings, partners’ capital and cash flow for the six-month period then ended (collectively, the “Financial Statements”) have been delivered to Buyer. The Financial Statements have been prepared in accordance with GAAP applied on a consistent basis throughout the period involved, subject to normal and recurring year-end adjustments (the effect of which will not be material to the Business) and the absence of notes. The Financial Statements are based on the books and records of the Business, and fairly present in all material respects the financial condition of the Business as of the respective dates they were prepared and the results of the operations of the Business for the periods indicated. The balance sheet of the Business as of December 31, 2025 is referred to herein as the “Balance Sheet” and the date thereof as the “Balance Sheet Date” and the balance sheet of the Business as of June 30, 2026 is referred to herein as the “Interim Balance Sheet” and the date thereof as the “Interim Balance Sheet Date”. Seller maintains a standard system of accounting for the Business established and administered in accordance with GAAP.
Section 4.05 Undisclosed Liabilities. Seller has no Liabilities with respect to the Business, except (a) those which are adequately reflected or reserved against in the Interim Balance Sheet as of the Interim Balance Sheet Date, and (b) those which have been incurred in the ordinary course of business consistent with past practice since the Interim Balance Sheet Date and which are not, individually or in the aggregate, material in amount.
Section 4.06 Absence of Certain Changes, Events and Conditions. Since the Balance Sheet Date, the Business has been conducted in the ordinary course of business consistent with past practice, and there has not been any:
(a) event, occurrence, or development that has had, or would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect;
(b) material change in any method of accounting or accounting practice for the Business, except as required by GAAP or as disclosed in the notes to the Financial Statements;
(c) entry into any Contract that would constitute a Material Contract;
(d) incurrence, assumption or guarantee of any indebtedness for borrowed money in connection with the Business except unsecured current obligations and Liabilities incurred in the ordinary course of business consistent with past practice;
| -23- |
(e) transfer, assignment, sale, or other disposition of any of the Acquired Assets shown or reflected in the Balance Sheet, except for the sale of Inventory in the ordinary course of business;
(f) cancellation of any debts or claims or amendment, termination or waiver of any rights constituting Acquired Assets;
(g) transfer or assignment of or grant of any license or sublicense under or with respect to any Intellectual Property Assets or Intellectual Property Agreements (except non-exclusive licenses or sublicenses granted in the ordinary course of business consistent with past practice);
(h) abandonment or lapse of or failure to maintain in full force and effect any Intellectual Property Registration, or failure to take or maintain reasonable measures to protect the confidentiality or value of any confidential Know-how included in the Intellectual Property Assets;
(i) material damage, destruction or loss, or any material interruption in use, of any Acquired Assets, whether or not covered by insurance;
(j) acceleration, termination, material modification to or cancellation of any Assigned Contract or Regulatory Authorization;
(k) material capital expenditures which would constitute an Assumed Liability;
(l) imposition of any Encumbrance upon any of the Acquired Assets;
(m) any loan to (or forgiveness of any loan to), or entry into any other transaction with, any current or former partners, officers, or employees of the Business;
(n) adoption of any plan of merger, consolidation, reorganization, liquidation, or dissolution or filing of a petition in bankruptcy under any provisions of federal or state bankruptcy Law or consent to the filing of any bankruptcy petition against it under any similar Law;
(o) Contract to do any of the foregoing, or any action or omission that would result in any of the foregoing.
Section 4.07 Material Contracts.
(a) Section 4.07(a) of the Disclosure Schedules lists each of the following Contracts (x) to which Seller is a party or by which it is bound in connection with the Business or the Acquired Assets or (y) that are Assigned Contracts (such listed Contracts, being “Material Contracts”):
(i) all Intellectual Property Agreements, other than Incidental Licenses; and
(ii) all Contracts involving aggregate annual consideration in excess of $[***] and which, in each case, cannot be cancelled without penalty or without more than [***] notice.
| -24- |
(b) Each Material Contract is in full force and effect and is a valid and binding agreement enforceable against Seller and, to Seller’s Knowledge, the other party or parties thereto, in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium or similar Laws affecting creditors’ rights generally or by general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or at law). None of Seller or, to Seller’s Knowledge, any other party thereto is in material breach of or default under (or is alleged to be in breach of or default under), and Seller has not provided or received any written notice of any intention to terminate, any Material Contract. To the Knowledge of Seller, no event or circumstance has occurred that, with notice or lapse of time or both, would constitute an event of default under any Material Contract or result in a termination thereof or would cause or permit the acceleration or other changes of any right or obligation or the loss of any benefit thereunder. Complete and correct copies of each Material Contract (including all modifications, amendments, and supplements thereto and waivers thereunder) have been made available to Buyer. There are no material disputes pending or, to Seller’s Knowledge, threatened under any Contract included in the Acquired Assets.
Section 4.08 Title to Acquired Assets. Seller has good and valid title to, or a valid leasehold interest in, all of the Acquired Assets. All such Acquired Assets (including leasehold interests) are free and clear of Encumbrances except for the following (collectively referred to as “Permitted Encumbrances”):
(a) those items set forth in Section 4.08 of the Disclosure Schedules;
(b) liens for Taxes not yet due and payable;
(c) Encumbrances of lessors, lessees, sublessors, sublessees, licensors, or licensees to the extent arising under and in accordance with the terms of Contracts made available to Buyer prior to the date of this Agreement and arising or incurred in the ordinary course of business;
(d) non-exclusive licenses of Intellectual Property granted in the ordinary course of business; or
(e) mechanics’, carriers’, workmen’s, repairmen’s, purchase money or other like liens arising or incurred in the ordinary course of business consistent with past practice or amounts that are not delinquent and which are not, individually or in the aggregate, material to the Business or the Acquired Assets.
Section 4.09 Condition and Sufficiency of Assets. The Acquired Assets constitute all of the (a) material rights, property and assets used by Seller in connection with the research, development, manufacture, and commercialization of APT-1011, and are sufficient to permit Buyer to continue the development, manufacture, and commercialization of APT-1011 immediately following the Closing in substantially the same manner as conducted by Seller prior to the Closing and (b) except with respect to general & administrative functions, rights, property, and assets necessary to conduct the Business as currently conducted. None of the Excluded Assets are material to the Business or APT-1011.
Section 4.10 Intellectual Property.
(a) Section 4.10(a) of the Disclosure Schedules contains a correct, current, and complete list of: (i) all Intellectual Property Registrations, specifying as to each, as applicable: the record owner, the title, mark, or design; the jurisdiction by or in which it has been issued, registered or filed; the patent, registration or application serial number; the issue, registration or filing date; and the current status, including any lapse, abandonment, withdrawal, revocation, cancellation, or disclaimer and the particular claims affected; (ii) all unregistered Trademarks included in the Intellectual Property Assets; and (iii) all proprietary Software included in the Intellectual Property Assets.
| -25- |
(b) Section 4.10(b) of the Disclosure Schedules contains a correct, current and complete list of all Intellectual Property Agreements, other than Incidental Licenses, specifying for each the date, title, and parties thereto, and separately identifying the Intellectual Property Agreements, other than Incidental Licenses: (i) under which Seller is a licensor or otherwise grants to any Person any right or interest relating to any Intellectual Property Asset; and (ii) under which Seller is a licensee or otherwise granted any right or interest relating to the Intellectual Property of any Person.
(c) Seller is the sole and exclusive legal and beneficial owner of all right, title and interest in and to the Owned Intellectual Property, and has the valid and enforceable right to use all Licensed Intellectual Property, in each case, free and clear of Encumbrances other than Permitted Encumbrances. The Intellectual Property Assets and Licensed Intellectual Property are all of the Intellectual Property necessary to operate the Business as presently conducted. Seller has entered into binding, valid and enforceable written Contracts with each current and former employee and independent contractor who is or was involved in or has contributed to the invention, creation, or development of any Intellectual Property Assets during the course of employment or engagement with Seller whereby such employee or independent contractor (i) acknowledges Seller’s exclusive ownership of all Intellectual Property Assets that constitute Owned Intellectual Property and are invented, created or developed by such employee or independent contractor within the scope of his or her employment or engagement with Seller; (ii) grants to Seller a present, irrevocable assignment of any ownership interest such employee or independent contractor may have in or to such Intellectual Property, to the extent such Intellectual Property does not constitute a “work made for hire” under applicable Law; and (iii) irrevocably waives any right or interest, including any moral rights, regarding such Intellectual Property, to the extent permitted by applicable Law. Seller has made available to Buyer true and complete copies of all such Contracts. All assignments and other instruments necessary to establish, record, and perfect Seller’s ownership interest in the Intellectual Property Registrations, including assignments from inventors and through each predecessor in title, have been validly executed, delivered, and filed with the relevant Governmental Authorities and authorized registrars, except where failure to do so would not reasonably be expected to cause a Material Adverse Effect.
(d) Neither the execution, delivery, nor performance of this Agreement, nor the consummation of the transactions contemplated hereunder, will result in the loss or impairment of or payment of any additional amounts with respect to the Buyer’s right to own or use any Intellectual Property Assets in the conduct of the Business as currently conducted. Immediately following the Closing, all Intellectual Property Assets will be owned or available for use by Buyer on identical terms as they were owned or available for use by Seller immediately prior to the Closing, including the benefit of any applicable standstill or covenant not to sue, challenge, or enforce under the Assigned Contracts.
(e) All Intellectual Property Registrations are valid, enforceable, subsisting and in full force and effect, provided that the foregoing representation is given to Seller’s Knowledge with respect to Patents. Section 4.10(e) of the Disclosure Schedules identifies each missed filing or payment, lapse, abandonment, withdrawal, revocation, cancellation, or disclaimer affecting any item listed or required to be listed in Section 4.10(a)(i) of the Disclosure Schedules, the date thereof, any remedial action taken, and any unexpired deadline for further processing, revival, restoration, or re-establishment. Seller has taken all necessary steps to maintain and enforce the Owned Intellectual Property and Licensed Intellectual Property for which it has enforcement rights and to preserve the confidentiality of all confidential Know-how included in the Intellectual Property Assets, including by requiring all Persons having access thereto to execute binding, written non-disclosure agreements. All required filings and fees related to the Intellectual Property Registrations have been timely submitted and paid to the relevant Governmental Authorities and authorized registrars. Seller has provided Buyer or its designated legal counsel with true and complete copies of all file histories, documents, certificates, office actions, correspondence, assignments, and other instruments relating to the Intellectual Property Registrations.
| -26- |
(f) The conduct of the Business, including the use of the Intellectual Property Assets and Licensed Intellectual Property in connection therewith, has not infringed, misappropriated, or otherwise violated the Intellectual Property or other rights of any Person, provided that the foregoing representation is made only to Seller’s Knowledge with respect to Patents. To the Knowledge of Seller, no Person has infringed, misappropriated, or otherwise violated any Intellectual Property Assets or Licensed Intellectual Property.
(g) There are no Actions pending (including any opposition, cancellation, revocation, review, or other proceeding), or, to Seller’s Knowledge, threatened (including in the form of offers to obtain a license): (i) alleging any infringement, misappropriation, or other violation of the Intellectual Property of any Person by Seller in the conduct of the Business; (ii) challenging the validity, enforceability, registrability, patentability, or ownership of any Intellectual Property Assets; (iii) by or on behalf of Seller alleging any infringement, misappropriation, or other violation by any Person of any Intellectual Property Assets; or (iv) concerning the scope, enforceability, or breach of any Intellectual Property Agreement. Seller is not aware of any facts or circumstances that would reasonably be expected to give rise to any such Action. Seller is not subject to any outstanding or prospective Governmental Order (including any motion or petition therefor) that does or would reasonably be expected to restrict or impair the use of any Intellectual Property Assets or Licensed Intellectual Property.
Section 4.11 Inventory. All Inventory relating to the Products, whether or not reflected in the Interim Balance Sheet, consists of a quality and quantity usable in the ordinary course of business consistent with past practice, except for obsolete, damaged, defective or slow-moving items that have been written off or written down to fair market value or for which adequate reserves have been established. All such Inventory is owned by Seller free and clear of all Encumbrances, except Permitted Encumbrances, and no such Inventory is held on a consignment basis. The quantities of each item of such Inventory (whether raw materials, work-in-process, or finished goods) are not excessive, but are reasonable in the present circumstances of Seller.
Section 4.12 Customers and Suppliers.
(a) Section 4.12(a) of the Disclosure Schedules sets forth with respect to the Business (i) the [***] of Seller based on aggregate consideration to Seller for goods or services rendered for each of the [***] most recent fiscal years (collectively, the “Material Customers”); and (ii) [***] during such periods. Seller has not received any notice, and to Seller’s Knowledge has no reason to believe, that any of the Material Customers has ceased, or intends to cease after the Closing, to use the goods or services of the Business or to otherwise terminate or materially reduce its relationship with the Business.
(b) Section 4.12(b) of the Disclosure Schedules sets forth with respect to the Business (i) the [***] of Seller based on consideration paid for goods or services rendered for each of the [***] most recent fiscal years (collectively, the “Material Suppliers”); and (ii) [***] during such periods. Seller has not received any notice, and to Seller’s Knowledge has no reason to believe, that any of the Material Suppliers has ceased, or intends to cease, to supply goods or services to the Business or to otherwise terminate or materially reduce its relationship with the Business.
| -27- |
Section 4.13 Insurance. Section 4.13 of the Disclosure Schedules sets forth (a) a true and complete list of all current policies or binders of product liability, umbrella liability, clinical trial and other casualty and liability insurance maintained by Seller or its Affiliates and relating to the Products, the Acquired Assets or the Assumed Liabilities (collectively, the “Insurance Policies”); and (b) with respect to the Products, the Acquired Assets or the Assumed Liabilities, a list of all pending claims and the claims history for Seller since January 1, 2021. There are no claims related to the Products, the Acquired Assets or the Assumed Liabilities pending under any Insurance Policies as to which coverage has been questioned, denied, or disputed or in respect of which there is an outstanding reservation of rights. Neither Seller nor any of its Affiliates has received any written notice of cancellation of, premium increase with respect to, or alteration of coverage under, any of the Insurance Policies. All premiums due on the Insurance Policies have either been paid or, if not yet due, accrued. All the Insurance Policies (a) are in full force and effect and enforceable in accordance with their terms; (b) to Seller’s Knowledge, are provided by carriers who are financially solvent; and (c) have not been subject to any lapse in coverage. None of Seller or any of its Affiliates is in default under, or has otherwise failed to comply with, in any material respect, any provision contained in any Insurance Policy. The Insurance Policies are of the type and in the amounts customarily carried by Persons developing and commercializing products similar to the Products and are sufficient for compliance with all applicable Laws and Contracts to which Seller is a party or by which it is bound. True and complete copies of the Insurance Policies have been made available to Buyer.
Section 4.14 Legal Proceedings; Governmental Orders.
(a) There are no Actions pending or, to Seller’s Knowledge, threatened against or by Seller (i) relating to or affecting the Business, the Products, the Acquired Assets, or the Assumed Liabilities; or (ii) that challenge or seek to prevent, enjoin, or otherwise delay the transactions contemplated by this Agreement. No event has occurred or circumstances exist that may give rise to, or serve as a basis for, any such Action.
(b) There are no outstanding Governmental Orders and no unsatisfied judgments, penalties, or awards against, relating to or affecting the Business, the Products, or the Acquired Assets.
Section 4.15 Compliance With Laws; Regulatory Authorizations.
(a) Seller has complied, and is now complying, with all Laws applicable to the conduct of the Business as currently conducted or the ownership and use of the Acquired Assets in all material respects.
(b) All Regulatory Authorizations reasonably required for Seller to conduct the Business as currently conducted or for the ownership and use of the Acquired Assets have been obtained by Seller and are valid and in full force and effect. All fees and charges with respect to such Regulatory Authorizations as of the date hereof have been paid in full. Section 4.15(b) of the Disclosure Schedules lists all current Regulatory Authorizations issued to Seller which are related to the conduct of the Business as currently conducted or the ownership and use of the Acquired Assets, including the names of the Regulatory Authorizations and their respective dates of issuance and expiration. Seller has complied and is now complying in all material respects with the terms of all Regulatory Authorizations listed on Section 4.15(b) of the Disclosure Schedules. No event has occurred that, with or without notice or lapse of time or both, would reasonably be expected to result in the revocation, suspension, lapse, or limitation of any Regulatory Authorization set forth in Section 4.15(b) of the Disclosure Schedules.
Section 4.16 Environmental Matters.
(a) The operations of Seller with respect to the Business and the Acquired Assets are currently and have at all times been in compliance in all material respects with all Environmental Laws and all Environmental Permits required for the ownership, lease, operation, or use of the Acquired Assets. Seller has not received from any Person, with respect to the Business or the Acquired Assets, any: (i) Environmental Notice or Environmental Claim; or (ii) written request for information pursuant to any Environmental Law, which, in each case, either remains pending or unresolved, or is the source of ongoing obligations or requirements as of the Closing Date.
| -28- |
(b) Section 4.16 of the Disclosure Schedules contains a true, correct, and complete list of all Environmental Permits required under Environmental Laws for the operation of the Business and the Acquired Assets as currently conducted. All such Environmental Permits are in full force and effect, no appeal or renewal procedures are pending, and there are no proceedings to revoke, modify, or suspend any such permit. To Seller’s Knowledge, no event has occurred that would prevent the valid transfer of such Environmental Permits to Buyer at Closing.
(c) Seller has not retained or assumed, by contract or operation of Law, any liabilities or obligations of third parties under Environmental Law.
(d) Seller is not aware of nor reasonably anticipates, as of the Closing Date, any condition, event or circumstance concerning the Release or regulation of Hazardous Materials that might, after the Closing Date, prevent, impede or materially increase the costs associated with the ownership, lease, operation, performance or use of the Business or the Acquired Assets as currently carried out. There are no Hazardous Materials present at the facilities of Seller in a manner, quantity, or condition that violates any Environmental Law or requires remediation, monitoring, or cleanup under any Environmental Law.
(e) Without limiting the generality of the foregoing, Seller has at all times handled, stored, used, manufactured, packaged, transferred, and disposed of all active pharmaceutical ingredients, highly potent compounds, controlled substances, biological agents, and medical or laboratory wastes in strict compliance with all applicable Environmental Laws, biosafety standards, and institutional approvals.
(f) There are no pending or, to Seller’s Knowledge, threatened Environmental Claims, lawsuits, administrative actions, or investigations against Seller relating to the Acquired Assets. Seller has not sent, transported, or arranged for the transport of any Hazardous Materials to any off-site location that is currently listed or proposed for listing on the National Priorities List (Superfund) or that is otherwise the subject of an environmental cleanup action or liability.
(g) Seller has delivered to Buyer true, correct, and complete copies of all environmental site assessments, environmental audits, safety data sheets for proprietary compounds, occupational exposure limit assessments, wastewater discharge logs, and air emissions monitoring reports in Seller’s possession or control relating to the Acquired Assets.
Section 4.17 FDA Matters.
(a) Seller holds, and at all times has held, all Regulatory Authorizations issued or required by the FDA or any other Governmental Authority exercising comparable authority necessary to conduct the Business as currently conducted, including the research, development, and clinical testing of the Product Candidate, and all such Regulatory Authorizations are listed on Section 4.17(a) of the Disclosure Schedules.
(b) Seller is, and at all times has been, in compliance in all material respects with all applicable Laws, guidance documents, and orders administered or issued by any Governmental Authority applicable to the Product Candidate or the Business, including the U.S. Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, and the regulations of the FDA promulgated thereunder (collectively, “Applicable Regulatory Laws”).
| -29- |
(c) There is no pending, and Seller has not received any oral or written notice, and has no Knowledge, of any threatened, Action by any Governmental Authority alleging noncompliance with any Applicable Regulatory Laws.
(d) Section 4.17(d) of the Disclosure Schedules sets forth a true, correct, and complete list of each investigational new drug application (“IND”) filed by or on behalf of Seller with the FDA with respect to the Product Candidate, including the IND number, sponsor of record, filing date, and current status. Seller has made available to Buyer true, correct, and complete copies of each IND referenced in Section 4.17(d) of the Disclosure Schedules, together with all amendments, supplements, safety reports, annual reports, and correspondence to or from the FDA relating thereto. Seller’s IND for the Product Candidate is in full force and effect, has not been withdrawn, suspended, or terminated, and is not subject to any partial or full clinical hold, and Seller has not received any notice from the FDA proposing or threatening any such hold, withdrawal, suspension, or termination. Seller is the sole sponsor of record of such IND, and no consent of any Third Party is required for Seller to transfer sponsorship of such IND to Buyer, other than filings or notifications required by Applicable Regulatory Laws.
(e) Section 4.17(e) of the Disclosure Schedules sets forth a true, correct, and complete list of each meeting, teleconference, and written correspondence between Seller and the FDA (including Type A, B, and C meetings) relating to the Product Candidate, and Seller has made available to Buyer true, correct, and complete copies of all minutes, briefing books, and correspondence relating to each such interaction. Except as set forth in Section 4.17(e) of the Disclosure Schedules, FDA has not communicated to Seller in writing or, to Seller’s Knowledge, orally that (i) the design, endpoints, duration or statistical analysis plan of the confirmatory Phase 3 study is inadequate to support approval, (ii) an additional efficacy study beyond the confirmatory Phase 3 study will be required, or (iii) the existing safety database or CMC package is inadequate to support filing of an NDA. Seller has not materially deviated from any agreement or commitment with FDA concerning the confirmatory Phase 3 study. Section 4.17(e) of the Disclosure Schedules describes the current status of Seller’s discussions with FDA concerning the design, endpoints, statistical analysis plan, timing, and other material elements of the confirmatory Phase 3 study, including each material matter that has not been agreed with or confirmed by FDA.
(f) The Product Candidate has received orphan drug designation from the FDA and from the European Medicines Agency (“EMA”) for the treatment of eosinophilic esophagitis, and Fast Track designation from the FDA, each of which remains in full force and effect and has not been revoked, withdrawn, or, to Seller’s Knowledge, threatened to be revoked or withdrawn. Seller is the owner of the FDA orphan-drug designation and the sponsor of record of the IND associated with the Fast Track designation. Seller has timely submitted all filings and taken all actions required to maintain the FDA orphan drug designation and Fast Track designation, and no act or omission by Seller has occurred that would reasonably be expected to impair the continued availability of either such designation following the Closing.
(g) Section 4.17(g) of the Disclosure Schedules sets forth a true, correct, and complete list of all designations, including orphan drug designation, Fast Track designation, breakthrough therapy designation, priority review, rare pediatric disease designation, and any equivalent designations under the Laws of any other jurisdiction, that Seller has sought, obtained, been denied, or had revoked with respect to the Product Candidate. Except as set forth in Section 4.17(g) of the Disclosure Schedules, FDA has not denied or rejected any designation or other expedited regulatory status sought by Seller with respect to the Product Candidate.
(h) To the Knowledge of Seller, there is no fact or circumstance, including any competing orphan drug designation or approval by a Third Party for the same indication, which would reasonably be expected to result in the loss, revocation, or narrowing of any designation or exclusivity referenced in this Section 4.17.
| -30- |
(i) Section 4.17(i) of the Disclosure Schedules sets forth a true, correct, and complete list of each clinical trial of the Product Candidate sponsored, conducted, or controlled by or on behalf of Seller, including the FLUTE 1, FLUTE 2, and FLUTE 3 studies and the ongoing expanded access program, and Seller has made available to Buyer all current status, phase, and material top-line or interim results of each. Seller has made available to Buyer a description of the planned confirmatory Phase 3 study, including the current status of protocol and study design development, the design, endpoints, and statistical analysis plan currently proposed by Seller.
(j) Each clinical trial referenced in Section 4.17(i) of the Disclosure Schedules has been, and to the extent ongoing is being, conducted in all material respects in accordance with the applicable protocol, Good Clinical Practice requirements of the FDA, and all Applicable Regulatory Laws, including requirements relating to informed consent and institutional review board or independent ethics committee oversight and approval.
(k) Seller has not received any notice from the FDA or any other Governmental Authority, and, to Seller’s Knowledge, no fact or circumstance exists, indicating that any data generated in the FLUTE 1, FLUTE 2, or FLUTE 3 studies, or any data generated to date in connection with the confirmatory Phase 3 study is unreliable, was generated other than in compliance with Good Clinical Practice requirements of the FDA, or is otherwise insufficient to support the planned new drug application (“NDA”) submission for the Product Candidate.
(l) No clinical investigator, laboratory, institution, institutional review board, or contract research organization, Seller in its capacity as sponsor, or any prior sponsor, involved in the conduct of any clinical trial referenced in Section 4.17(i) of the Disclosure Schedules has been the subject of an FDA Application Integrity Policy referral, disqualification proceeding, or debarment action, and, to Seller’s Knowledge, no such action is threatened. Seller has made available to Buyer all material FDA inspectional communications relating to Seller, any prior sponsor, or any such clinical investigator, laboratory, institution, institutional review board, or contract research organization, in connection with the Product Candidate. Section 4.17(l) of the Disclosure Schedules identifies each FDA Bioresearch Monitoring inspection of Seller, any prior sponsor, or any clinical trial site, investigator, institutional review board, contract research organization, or laboratory involved in any such clinical trial of Product Candidate and describes any resulting Form FDA 483, Establishment Inspection Report, Warning Letter, Notice of Initiation of Disqualification Proceedings and Opportunity to Explain, or other material written FDA communication.
(m) Section 4.17(m) of the Disclosure Schedules sets forth a true, correct, and complete list of each facility at which the Product Candidate (or any component or intermediate thereof) is or has been manufactured, tested, packaged, or stored, whether owned by Seller or by a third-party contract manufacturing organization, and identifies which party owns or controls each such facility. Each such facility is, and at all times material to the manufacture of the Product Candidate has been, operated in compliance in all material respects with current Good Manufacturing Practice requirements of the FDA and all other applicable Laws. Seller has made available to Buyer true, correct, and complete copies of all FDA Form 483 observations, Establishment Inspection Reports, warning letters, untitled letters, and other written communications from any Governmental Authority relating to any such facility, and Section 4.17(m) of the Disclosure Schedules describes the current status of Seller’s or the applicable contract manufacturer’s response to and remediation of each such observation. No such facility is subject to a pending or, to Seller’s Knowledge, threatened FDA import alert, injunction, consent decree, or shutdown order. Section 4.17(m) of the Disclosure Schedules also identifies each material open or unresolved deviation, out-of-specification or out-of-trend result, corrective or preventive action, batch failure or rejection, stability failure, data-integrity investigation, and supplier or contract manufacturer quality issue relating to the Product Candidate, and accurately describes the current status thereof.
| -31- |
(n) Section 4.17(n) of the Disclosure Schedules describes Seller’s current NDA submission timeline for the Product Candidate and identifies any dates or milestones for such submission that have been proposed to, or agreed with, the FDA.
(o) To Seller’s Knowledge, the nonclinical, clinical, and chemistry, manufacturing, and controls data generated to date with respect to the Product Candidate, taken as a whole, do not contain any deficiency that would reasonably be expected to result in the FDA refusing to file, or issuing a complete response letter with respect to, an NDA for the Product Candidate based on the development program as currently designed.
(p) Seller has satisfied, or has an approved deferral, waiver, or plan with respect to, all applicable requirements of the Pediatric Research Equity Act and Section 505B of the Federal Food, Drug, and Cosmetic Act with respect to the Product Candidate, including any requirement to timely submit an initial pediatric study plan and any required amendments thereto, and Section 4.17(p) of the Disclosure Schedules describes the current status of any such plan, deferral, or waiver.
(q) Neither Seller nor, to Seller’s Knowledge, any of its general partners, officers, directors, employees, or agents has been convicted of any crime or engaged in any conduct that would reasonably be expected to result in debarment under 21 U.S.C. § 335a, exclusion from participation in any federal healthcare program, or disqualification under 21 C.F.R. § 312.70, and no such debarment, exclusion, or disqualification proceeding is pending or, to Seller’s Knowledge, threatened.
(r) Seller has not received any FDA warning letter, untitled letter, notice of adverse finding, or similar written communication alleging material noncompliance with applicable Laws that remains unresolved as of the date hereof.
(s) Seller has established and maintains policies and procedures reasonably designed to ensure compliance with all applicable adverse event and safety reporting obligations under applicable Laws with respect to the Product Candidate, including IND safety reporting obligations, and has made all such reports required to be made prior to the date hereof in all material respects on a timely basis. Section 4.17(s) of the Disclosure Schedules sets forth a true, correct, and complete list of all serious adverse events reported in connection with any clinical trial of the Product Candidate, and, to Seller’s Knowledge, there is no material safety signal or other safety-related finding with respect to the Product Candidate that has not been fully and accurately disclosed to Buyer.
(t) The Product Candidate, and all preclinical and clinical testing thereof, has been designed, manufactured, tested, labeled, packaged, and stored in all material respects in accordance with the specifications, protocols, and applicable Laws in effect at the relevant time, including all applicable current Good Manufacturing Practice, Good Clinical Practice, and Good Laboratory Practice requirements of the FDA. Seller has not received any notice or communication from the FDA, EMA, or any other Governmental Authority requiring or recommending the recall, market withdrawal, field correction, seizure, suspension, or clinical hold of the Product Candidate or any clinical trial thereof, and no such action is pending, threatened, or, to Seller’s Knowledge, under consideration by any Governmental Authority. There have been no product safety, quality, or manufacturing defects identified with respect to the Product Candidate that have not been remediated or fully and accurately disclosed to Buyer. Seller has timely and accurately reported to the FDA, EMA, and each other applicable Governmental Authority all adverse events, serious adverse events, safety signals, and other safety-related information concerning the Product Candidate required to be reported under applicable Law, and has made available to Buyer complete and correct copies of all such reports. To Seller’s Knowledge, there are no facts, circumstances, or unreported safety data that would reasonably be expected to result in a recall, market withdrawal, clinical hold, safety-related labeling change, or other adverse regulatory action with respect to the Product Candidate.
| -32- |
(u) All material applications, submissions, reports, and other information submitted by or on behalf of Seller to FDA with respect to the Product Candidate were true, complete, and accurate in all material respects when submitted or were subsequently corrected or supplemented, and no material correction or supplement remains required. All material clinical, nonclinical, safety, statistical, and CMC data included in the Product Records are complete and accurate in all material respects. Neither Seller nor, to Seller’s Knowledge, any Person acting on Seller’s behalf has made a materially false or fraudulent statement to FDA, omitted a material fact required to be disclosed, or engaged in conduct that would reasonably be expected to cause FDA to invoke its Application Integrity Policy.
(v) Section 4.17(v) of the Disclosure Schedules identifies each drug master file, letter of authorization, or other right of reference relied upon or intended to be relied upon in connection with the Product Candidate. Each such right is in effect and, to Seller’s Knowledge, is not subject to threatened withdrawal, termination, or material limitation, and Seller has made available to Buyer all material FDA communications concerning any such item.
(w) Seller owns, or has a valid and transferable right to use and to permit Buyer to use, all clinical and nonclinical data, results, records, samples, specimens, case report forms, and other materials included in or relating to the Product Records and the clinical trials of the Product Candidate (including the FLUTE 1, FLUTE 2, and FLUTE 3 studies and, to the extent applicable, the confirmatory Phase 3 study). No Contract with any contract research organization, clinical site, investigator, laboratory, or other Person, and no informed consent, institutional review board or independent ethics committee approval, restricts, conditions, or otherwise limits the transfer of such data, records, samples, or materials to Buyer or Buyer’s use thereof for the development, regulatory, manufacturing, and commercialization of the Products, including use and reliance in and in support of any IND, NDA, or other regulatory submission for the Product Candidate. To Seller’s Knowledge, the informed consents, institutional review board or independent ethics committee approvals, and clinical trial, CRO, and investigator agreements applicable to each clinical trial of the Product Candidate do not restrict the transfer of the applicable data, records, samples, and materials to Buyer and their use by Buyer for such purposes, in each case in compliance with Applicable Regulatory Laws.
(x) Except as set forth in Section 4.17(x) of the Disclosure Schedules, there is no material outstanding or overdue request, commitment, deficiency, information request, meeting follow-up, or other regulatory obligation to FDA relating to the Product Candidate, and Seller has not received any written communication from FDA requiring or recommending a risk evaluation and mitigation strategy (REMS) or other post-approval risk-management requirement as a condition of approval.
| -33- |
Section 4.18 Employee Benefit Matters.
(a) Section 4.18(a) of the Disclosure Schedules sets forth a true and complete list of each material “employee benefit plan” (as such term is used, without regard to any exclusion for governmental or church plans, in the manner defined by ERISA), and each other material bonus, deferred compensation, incentive, equity or equity-based, severance, retention, change-in-control, fringe benefit, or other compensation or benefit plan, program, agreement, or arrangement, in each case sponsored, maintained, or contributed to by Seller for the benefit of any current or former employee, officer, or director of the Business, excluding Incidental Licenses, at-will employee offer letters terminable without severance and independent contractor agreements terminable by Seller for convenience with no more than [***] notice; provided that, no such Incidental License, offer letter or independent contractor agreement contains a change-of-control, acceleration or similar provision triggered by the transactions contemplated by this Agreement (each, a “Benefit Plan”).
(b) No Benefit Plan, and none of its assets, will be transferred to Buyer, and Buyer shall not assume, and shall have no Liability of any kind with respect to, any Benefit Plan, whether arising before, on, or after the Closing Date, including any Liability relating to funding, benefit accruals, participant claims, or plan administration.
(c) Each Benefit Plan has been established, operated, and administered in all material respects in accordance with its terms and with applicable Law, including ERISA and the Code.
(d) Neither Seller nor any ERISA Affiliate sponsors, maintains, contributes to, or has within the preceding six years sponsored, maintained, or contributed to, any plan subject to Title IV of ERISA or Section 412 of the Code, or any “multiemployer plan” (as defined in Section 3(37) of ERISA). No Benefit Plan is a “multiple employer welfare arrangement” and no Benefit Plan provides for post-employment or retiree welfare benefits, except as required under Section 4980B of the Code (COBRA) or similar applicable state law, at the sole expense of the covered individual or Seller.
(e) All contributions, premiums, and expenses required to be paid or accrued under each Benefit Plan have been timely paid or accrued in accordance with the terms of the applicable plan and applicable Law, and no material Liability with respect to any Benefit Plan has been or will be incurred by Buyer.
(f) Seller shall be solely responsible for offering and administering continuation coverage under COBRA (or any similar state Law) to all employees of the Business and their qualified beneficiaries who experience a qualifying event, including as a result of the transactions contemplated by this Agreement, and Buyer shall have no obligation to offer or administer any such continuation coverage.
Section 4.19 Employment Matters.
(a) Section 4.19(a) of the Disclosure Schedules sets forth a true and complete list of all employees, consultants, and independent contractors of Seller engaged in the operation of the Business as of the date of this Agreement, including each such Person’s title, work location, and employment status (full-time, part-time, or leave of absence). No employee of Seller will become an employee of Buyer as a result of the transactions contemplated by this Agreement, and Buyer shall have no obligation to offer employment to, hire, or assume any liability with respect to any employee of Seller.
(b) Seller is not a party to, and the Business is not subject to, any collective bargaining agreement, and there is no labor union, works council, or other labor organization representing or, to Seller’s Knowledge, purporting to represent any employee of the Business. There is no pending or, to Seller’s Knowledge, threatened labor strike, slowdown, work stoppage, or material labor dispute affecting the Business.
| -34- |
(c) Seller is, and for the past five (5) years has been, in compliance in all material respects with all applicable Laws respecting employment and employment practices, including those relating to wages, hours, overtime, classification of employees and independent contractors, discrimination, harassment, retaliation, immigration status verification (including Form I-9 compliance), and occupational health and safety.
(d) Because no employees of Seller are being hired by Buyer and the sale contemplated by this Agreement is a sale of assets, Seller is solely responsible for providing any notice required in connection with any “plant closing” or “mass layoff” (as those terms are defined in the WARN Act) resulting from the transactions contemplated by this Agreement, and Buyer shall have no notice or other obligation under the WARN Act arising from Seller’s actions prior to or in connection with the Closing.
(e) There is no pending or, to Seller’s Knowledge, threatened claim, charge, complaint, audit, or investigation against Seller relating to employment or labor matters affecting the Business before any Governmental Authority.
Section 4.20 Taxes.
(a) All Tax Returns with respect to the Business required to be filed by Seller for any Pre-Closing Tax Period have been, or will be, timely filed. Such Tax Returns are, or will be, true, complete, and correct in all respects. All Taxes due and owing by Seller (whether or not shown on any Tax Return) that relate to the Business have been, or will be, timely paid.
(b) Seller has withheld and paid each material Tax required to have been withheld and paid in connection with amounts paid or owing to any employee, independent contractor, creditor, customer, shareholder, or other party, and complied with all information reporting and backup withholding provisions of applicable Law.
(c) No extensions or waivers of statutes of limitations have been given or requested with respect to any Taxes of Seller.
(d) All deficiencies asserted, or assessments made, against Seller as a result of any examinations by any taxing authority have been fully paid.
(e) Seller is not a party to any Action by any taxing authority. There are no pending or, to Seller’s Knowledge, threatened Actions by any taxing authority against Seller.
(f) There are no Encumbrances for Taxes upon any of the Acquired Assets nor is any taxing authority in the process of imposing any Encumbrances for Taxes on any of the Acquired Assets (other than for current Taxes not yet due and payable).
(g) Seller is not a “foreign person” as that term is used in Treasury Regulations Section 1.1445-2.
(h) Seller is not, and has not been, a party to, or a promoter of, a “reportable transaction” within the meaning of Section 6707A(c)(1) of the Code and Treasury Regulations Section 1.6011-4(b).
(i) None of the Acquired Assets is (i) required to be treated as being owned by another person pursuant to the so-called “safe harbor lease” provisions of former Section 168(f)(8) of the Internal Revenue Code of 1954, as amended, (ii) subject to Section 168(g)(1)(A) of the Code, or (iii) subject to a disqualified leaseback or long-term agreement as defined in Section 467 of the Code.
| -35- |
(j) None of the Acquired Assets is tax-exempt use property within the meaning of Section 168(h) of the Code.
Section 4.21 Related Party Transactions. There are no Contracts or other arrangements involving the Business in which Seller, its Affiliates, or any of its or their respective directors, officers, or employees or any immediate family members thereof is a party, has a financial interest, or otherwise owns or leases any Acquired Asset.
Section 4.22 Data Privacy and Cybersecurity.
(a) Seller has complied, and is in compliance, in all material respects with (i) all applicable Laws relating to privacy, data protection, data security, and cybersecurity, (ii) all of Seller’s own posted or publicly available privacy policies and notices, and (iii) all applicable contractual and fiduciary obligations, in each case concerning the collection, generation, use, processing, storage, disclosure, transfer, security, and protection of personal information and clinical trial data relating to the Business or the Products (“Privacy Laws”).
(b) Seller has implemented and maintains commercially reasonable administrative, technical, physical, and organizational safeguards designed to protect the confidentiality, integrity, and availability of personal information and other confidential or proprietary information (including clinical trial data) in its possession, custody, or control, and to protect the information technology systems used in the Business against unauthorized access, use, disclosure, or modification.
(c) Seller has not experienced any actual, alleged, or suspected data breach, security incident, ransomware attack, unauthorized intrusion, or other cybersecurity incident involving personal information, clinical trial data, or any information technology system used in the Business or otherwise in Seller’s possession or control that resulted in, or would reasonably be expected to result in, unauthorized access to, or acquisition, use, disclosure, or loss of, such information requiring notice to any individual or Governmental Authority.
(d) Seller has not been the subject of, and has not received any notice of, any audit, investigation, enforcement action, complaint, claim, or other Action by any Governmental Authority, individual, or other Person relating to an actual, alleged, or suspected violation of any Privacy Laws or concerning Seller’s collection, use, processing, storage, transfer, or protection of personal information, in each case in connection with the conduct of the Business. To Seller’s Knowledge, there are no facts or circumstances that would reasonably be expected to give rise to any Action, liability, or notification obligation under any Privacy Laws in connection with the Business, the Products, or the Acquired Assets.
Section 4.23 CFIUS. Seller does not engage in (a) the design, fabrication, development, testing, production or manufacture of one or more “critical technologies” within the meaning of Section 721 of the Defense Production Act of 1950, as amended, including all implementing regulations thereof (the “DPA”); (b) the ownership, operation, maintenance, supply, manufacture, or servicing of “covered investment critical infrastructure” within the meaning of the DPA (where such activities are covered by column 2 of Appendix A to 31 C.F.R. Part 800); or (c) the maintenance or collection, directly or indirectly, of “sensitive personal data” of U.S. citizens within the meaning of the DPA. Seller has no current intention of engaging in such activities in the future.
| -36- |
Section 4.24 Sanctions, Anticorruption, Outbound.
(a) Neither Seller nor any of its Affiliates, nor any partner, director, officer, employee, or, to Seller’s Knowledge, agent, or other Person acting on behalf of Seller in connection with the Business or the Products, is, or during the past five (5) years has been: (i) a Person that is the subject of, or owned fifty percent (50%) or more or otherwise controlled by a Person that is the subject of, any sanctions administered or enforced by the U.S. Department of the Treasury’s Office of Foreign Assets Control, the U.S. Department of State, the United Nations Security Council, the European Union, or His Majesty’s Treasury (collectively, “Sanctions”); or (ii) organized, resident, or located in a country or territory that is the subject of comprehensive Sanctions (each of the foregoing a “Sanctioned Party”).
(b) Neither Seller nor any of its Affiliates, nor any partner, director, officer, employee, or, to Seller’s Knowledge, agent or other Person acting on behalf of Seller in connection with the Business or the Products, has, directly or indirectly: (i) used any funds of Seller for any unlawful contribution, gift, entertainment, or other unlawful payment relating to a political activity; (ii) made, offered, promised, or authorized any unlawful payment, gift, or thing of value, directly or indirectly, to any Government Official or any other Person, in each case, to improperly obtain or retain business or secure any improper advantage, in violation of the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”), the UK Bribery Act 2010, or any other applicable anti-bribery or anti-corruption Law of any jurisdiction in which Seller conducts the Business (collectively, “Anti-Corruption Laws”); or (iii) established or maintained any unlawful fund of corporate monies or other assets, or made any false or fictitious entries on the books or records of Seller, in each case relating to the Business.
(c) Seller has maintained systems of internal controls, including policies and procedures, reasonably designed to ensure compliance with the FCPA, other applicable Anti-Corruption Laws, applicable Sanctions, and export control Laws in connection with the Business.
(d) No Action by or before any Governmental Authority involving Seller with respect to the FCPA, Sanctions, or any other Anti-Corruption Law or export control Law is pending or, to Seller’s Knowledge, threatened.
| -37- |
Section 4.25 Securities Laws.
(a) Seller is acquiring the Upfront Shares solely for its own account for investment purposes and not with a view to, or for offer or sale in connection with, any distribution thereof. Seller acknowledges that the Upfront Shares are not registered under the Securities Act or any state securities laws, and that such Upfront Shares may not be transferred or sold except pursuant to the registration provisions of the Securities Act or pursuant to an applicable exemption therefrom and subject to state securities laws and regulations, as applicable. Seller is able to bear the economic risk of holding the Upfront Shares for an indefinite period (including total loss of its investment), and has sufficient knowledge and experience in financial and business matters so as to be capable of evaluating the merits and risk of its investment.
(b) Seller is an “accredited investor” as defined in Rule 501(a) of Regulation D under the Securities Act. Seller, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Upfront Shares, and has so evaluated the merits and risks of such investment.
(c) Seller understands that the Upfront Shares are being offered and sold to it in reliance upon specific exemptions from the registration requirements of foreign, federal and state securities laws and that Buyer is relying in part upon Seller’s statements in this Section 4.25 in order to determine the availability of such exemptions and the eligibility of Seller to acquire the Upfront Shares.
Section 4.26 Material Product Information. Seller has made available to Buyer all material information, data, reports, correspondence with Governmental Authorities, and other documents in Seller’s possession, custody, or control relating to the safety, efficacy, regulatory status, manufacturing, intellectual property, and commercial prospects of the Products, and there is no fact known to Seller that has specific application to the Products (other than general economic or industry conditions) and that materially adversely affects, or would reasonably be expected to have a Material Adverse Effect on, the Products, the Business, or the Acquired Assets that has not been disclosed to Buyer in writing.
Section 4.27 Brokers. No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection with the transactions contemplated by this Agreement or any Ancillary Document based upon arrangements made by or on behalf of Seller.
Section 4.28 No Other Representations. Except for the representations and warranties set forth in this Article IV and the related portions of the Disclosure Schedules, neither Seller nor any other Person has made any other representations or warranties of any kind or nature whatsoever, whether express or implied, about or pertaining to the Acquired Assets, the Business, Seller, or Seller’s assets or liabilities, including (a) the condition (physical or otherwise) of any assets, the present or future use of any assets or suitability for use in Buyer’s intended use or operation of such assets, or any implied warranties of merchantability or fitness for any particular purpose, (b) any future revenues, costs, expenditures, cash flow, results of operations, financial condition or prospects that may result from the ownership, use or sale of the Acquired Assets, (c) any other information or documents made available to Buyer or its Representatives, or (d) the condition of the Acquired Assets, including compliance with any Laws. Seller expressly disclaims, to the fullest extent permitted by applicable Law, any and all implied warranties arising by operation of Law, course of dealing, usage of trade, or otherwise, including any implied warranties of merchantability, fitness for a particular purpose, non-infringement, title (other than as expressly provided herein), quiet enjoyment, quiet possession, or condition, quality, or suitability of the Inventory.
| -38- |
ARTICLE V
Representations and warranties of buyer
Buyer represents and warrants to Seller that the statements contained in this Article V are true and correct as of the date hereof.
Section 5.01 Organization of Buyer. Buyer is a corporation duly organized, validly existing and in good standing under the Laws of the state of Delaware.
Section 5.02 Authority of Buyer. Buyer has full corporate power and authority to enter into this Agreement and the Ancillary Documents to which Buyer is or will be a party, to carry out its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. The execution and delivery by Buyer of this Agreement and any Ancillary Document to which Buyer is or will be a party, the performance by Buyer of its obligations hereunder and thereunder and the consummation by Buyer of the transactions contemplated hereby and thereby have been duly authorized by all requisite corporate action on the part of Buyer. This Agreement has been duly executed and delivered by Buyer, and (assuming due authorization, execution and delivery by Seller) this Agreement constitutes a legal, valid and binding obligation of Buyer enforceable against Buyer in accordance with its terms, except as may be limited by any bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other similar laws affecting the enforcement of creditors’ rights generally or by general principles of equity. When each Ancillary Document to which Buyer is or will be a party has been duly executed and delivered by Buyer (assuming due authorization, execution and delivery by each other party thereto), such Ancillary Document will constitute a legal and binding obligation of Buyer enforceable against it in accordance with its terms, except as may be limited by any bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other similar laws affecting the enforcement of creditors’ rights generally or by general principles of equity.
Section 5.03 No Conflicts; Consents. The execution, delivery and performance by Buyer of this Agreement and the Ancillary Documents to which it is or will be a party, and the consummation of the transactions contemplated hereby and thereby, do not and will not: (a) conflict with or result in a violation or breach of, or default under, any provision of the certificate of incorporation, by-laws or other organizational documents of Buyer; (b) conflict with or result in a violation or breach of any provision of any Law or Governmental Order applicable to Buyer; or (c) require the consent, notice or other action by any Person under any Contract to which Buyer is a party. No consent, approval, Regulatory Authorization, Governmental Order, declaration or filing with, or notice to, any Governmental Authority is required by or with respect to Buyer in connection with the execution and delivery of this Agreement and the Ancillary Documents to which Buyer is or will be a party and the consummation of the transactions contemplated hereby and thereby, except for consents, approvals, Regulatory Authorizations, Governmental Orders, declarations, filings or notices which, in the aggregate, would not have a material adverse effect on the ability of Buyer to consummate the transactions contemplated hereby on a timely basis.
Section 5.04 Brokers. No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection with the transactions contemplated by this Agreement or any Ancillary Document based upon arrangements made by or on behalf of Buyer.
| -39- |
Section 5.05 SEC Reports. Buyer has filed all SEC Reports required to be filed by it with the Securities and Exchange Commission (the “SEC”) under Sections 13, 14(a) and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) for the one year preceding the date of this Agreement and is in compliance with General Instruction I.A.3 of Form S-3. As of the time it was filed with the SEC, each of the filed SEC Reports (i) complied in all material respects with the applicable requirements of the Exchange Act and the rules and regulations promulgated thereunder, and (ii) did not, as of the time it was filed, or, if amended, as of the date of such amendment, contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. The consolidated financial statements of Buyer, including the notes thereto, included in the SEC Reports complied as to form in all material respects with the published rules and regulations of the SEC with respect thereto as of their respective dates, were prepared in accordance with GAAP (except as may be indicated in the notes thereto, except in the case of pro forma statements, or, in the case of unaudited financial statements, except as permitted under Form 10-Q under the Exchange Act), and fairly presented in all material respects the consolidated financial position of Buyer and its consolidated subsidiaries as of the respective dates thereof and the consolidated results of Buyer’s operations and cash flows for the periods indicated (subject to, in the case of unaudited statements, normal and recurring year-end audit adjustments).
Section 5.06 No Governmental Approval. No consent, approval, order or authorization of, or registration, declaration or filing with, any Governmental Authority, including any approval of or vote by the stockholders of Buyer under the rules of the Nasdaq Capital Market or otherwise, is required to be obtained or made by Buyer in connection with the execution, delivery or performance by Buyer of this Agreement or the consummation by Buyer of the transactions contemplated hereby, including the issuance of the Upfront Shares, other than the filings and notifications to FDA contemplated by this Agreement.
Section 5.07 Upfront Shares. The Upfront Shares to be issued and delivered to Seller in accordance with this Agreement have been duly and validly authorized and, upon issuance pursuant to the terms of this Agreement against full payment therefor in accordance with the terms of this Agreement, will be duly and validly issued, fully paid and non-assessable, and will be issued free and clear of all Encumbrances, except for restrictions on transfer under applicable federal and state securities Laws. None of such Upfront Shares, when so issued and delivered, shall be issued in violation of any applicable Law, agreement, arrangement, or commitment to which Buyer is a party or is subject to or in violation of any preemptive or similar rights of any Person. None of the Upfront Shares represent an interest in a “United States real property holding corporation” within the meaning of Section 897(c) of the Code.
Section 5.08 Legal Proceedings. There are no Actions pending or, to Buyer’s knowledge, threatened against or by Buyer or any Affiliate of Buyer that challenge or seek to prevent, enjoin, or otherwise delay the transactions contemplated by this Agreement. To Buyer’s knowledge, no event has occurred or circumstances exist that may give rise to or serve as a basis for any such Action.
Section 5.09 Sanctions. Neither Buyer, nor any of its officers, directors, employees, agents, stockholders or partners, is a Sanctioned Party.
Section 5.10 Not a Person of a Country of Concern. Except as otherwise disclosed in writing to Seller, Buyer is not a “person of a country of concern” as defined in 31 C.F.R. Part 850, as implemented or revised from time to time.
| -40- |
Section 5.11 CFIUS and DSP Representations. The Buyer does not engage in (a) the design, fabrication, development, testing, production or manufacture of one or more “critical technologies” within the meaning of the DPA; (b) the ownership, operation, maintenance, supply, manufacture, or servicing of “covered investment critical infrastructure” within the meaning of the DPA (where such activities are covered by column 2 of Appendix A to 31 C.F.R. Part 800); or (c) the maintenance or collection, directly or indirectly, of “sensitive personal data” of U.S. citizens within the meaning of the DPA. The Buyer has no current intention of engaging in such activities in the future. Buyer is a “U.S. person” as defined under 28 C.F.R. § 202.256.
Section 5.12 Anticorruption.
(a) Neither Buyer nor any of its Affiliates, nor any partner, director, officer, employee, or, to Buyer’s knowledge, agent or other Person acting on behalf of Buyer in connection with the Business or the Products, has, directly or indirectly: (i) used any funds of Buyer for any unlawful contribution, gift, entertainment, or other unlawful payment relating to a political activity; (ii) made, offered, promised, or authorized any unlawful payment, gift, or thing of value, directly or indirectly, to any Government Official or any other Person, in each case, to improperly obtain or retain business or secure any improper advantage, in violation of Anti-Corruption Laws; or (iii) established or maintained any unlawful fund of corporate monies or other assets, or made any false or fictitious entries on the books or records of Buyer, in each case relating to the Business.
(b) Buyer has maintained systems of internal controls, including policies and procedures, reasonably designed to ensure compliance with the FCPA, other applicable Anti-Corruption Laws, applicable Sanctions, and export control Laws in connection with the Business.
(c) No Action by or before any Governmental Authority involving Buyer with respect to the FCPA, Sanctions, or any other Anti-Corruption Law or export control Law is pending or, to Buyer’s knowledge, threatened.
ARTICLE VI
Covenants
Section 6.01 Employees and Employee Benefits.
(a) Seller shall bear any and all obligations and liability under the WARN Act resulting from employment losses arising as a result of the transactions contemplated hereby.
(b) Seller shall be solely responsible, and Buyer shall have no obligations whatsoever for, any compensation or other amounts payable to any current or former employee, officer, director, independent contractor or consultant of the Business, including, without limitation, hourly pay, commission, bonus, salary, accrued vacation, fringe, pension or profit sharing benefits or severance pay for any period relating to the service with Seller at any time on or prior to the Closing Date and Seller shall be responsible to pay all such amounts to all entitled persons on or prior to the date that such payments become due.
| -41- |
(c) Seller shall remain solely responsible for the satisfaction of all claims for medical, dental, life insurance, health accident or disability benefits brought by or in respect of current or former employees, officers, directors, independent contractors or consultants of the Business or the spouses, dependents or beneficiaries thereof, which claims relate to events occurring on or prior to the Closing Date. Seller also shall remain solely responsible for all workers’ compensation claims of any current or former employees, officers, directors, independent contractors, or consultants of the Business which relate to events occurring on or prior to the Closing Date. Seller shall pay, or cause to be paid, all such amounts to the appropriate persons as and when due.
Section 6.02 Confidentiality. From and after the Closing, Seller shall, and shall cause its Affiliates to, hold, and shall use its commercially reasonable efforts to cause its or their respective Representatives to hold, in confidence any and all information, whether written or oral, concerning the Business, except to the extent that Seller can show that such information (a) is generally available to and known by the public through no fault of Seller, any of its Affiliates or their respective Representatives; or (b) is lawfully acquired by Seller, any of its Affiliates or their respective Representatives from and after the Closing from sources which are not prohibited from disclosing such information by a legal, contractual or fiduciary obligation. If Seller or any of its Affiliates or their respective Representatives are compelled to disclose any information by judicial or administrative process or by other requirements of Law, Seller shall promptly notify Buyer in writing and shall disclose only that portion of such information which Seller is advised by its counsel in writing is legally required to be disclosed, provided that Seller shall use commercially reasonable efforts to obtain an appropriate protective order or other reasonable assurance that confidential treatment will be accorded such information.
Section 6.03 Non-Competition; Non-Solicitation.
(a) For a period of 12 months commencing on the Closing Date (the “Restricted Period”), Seller shall not, directly or indirectly, (i) engage in or assist others in engaging in the Restricted Business in the Territory; (ii) have an interest in any Person that engages directly or indirectly in the Restricted Business in the Territory in any capacity, including as a partner, shareholder, member, employee, principal, agent, trustee or consultant; or (iii) cause, induce or encourage any material client, customer, supplier or licensor of the Business, or any other Person who has a material business relationship with the Business, as of the Closing Date to terminate or modify any such relationship. Notwithstanding the foregoing, Seller may own, directly or indirectly, solely as an investment, securities of any Person traded on any national securities exchange if Seller is not a controlling Person of, or a member of a group which controls, such Person and does not, directly or indirectly, own five percent (5%) or more of any class of securities of such Person.
(b) During the Restricted Period, Seller shall not, and shall use commercially reasonable efforts to cause its Affiliates not to, directly or indirectly, hire or solicit any employee, consultant or independent contractor of Seller who is or was involved in the development, manufacture or commercialization of the Products during the Restricted Period, except pursuant to a general solicitation which is not directed specifically to any such individuals; provided, that nothing in this Section 6.03(b) shall prevent Seller or any of its Affiliates from hiring (i) any individual whose engagement has been terminated by Buyer or (ii) after [***] from the date of termination, any individual whose engagement has been terminated by the individual.
(c) Seller acknowledges that a breach or threatened breach of this Section 6.03 would give rise to irreparable harm to Buyer, for which monetary damages would not be an adequate remedy, and hereby agrees that in the event of a breach or a threatened breach by Seller of any such obligations, Buyer shall, in addition to any and all other rights and remedies that may be available to it in respect of such breach, be entitled to equitable relief, including a temporary restraining order, an injunction, specific performance and any other relief that may be available from a court of competent jurisdiction (without any requirement to post bond).
| -42- |
(d) Seller acknowledges that the restrictions contained in this Section 6.03 are reasonable and necessary to protect the legitimate interests of Buyer and constitute a material inducement to Buyer to enter into this Agreement and consummate the transactions contemplated by this Agreement. In the event that any covenant contained in this Section 6.03 should ever be adjudicated to exceed the time, geographic, product or service or other limitations permitted by applicable Law in any jurisdiction, then any court is expressly empowered to reform such covenant, and such covenant shall be deemed reformed, in such jurisdiction to the maximum time, geographic, product or service or other limitations permitted by applicable Law. The covenants contained in this Section 6.03 and each provision hereof are severable and distinct covenants and provisions. The invalidity or unenforceability of any such covenant or provision as written shall not invalidate or render unenforceable the remaining covenants or provisions hereof, and any such invalidity or unenforceability in any jurisdiction shall not invalidate or render unenforceable such covenant or provision in any other jurisdiction.
Section 6.04 Books and Records.
(a) For any reasonable purpose, for a period of seven years after the Closing, Buyer shall:
(i) retain the Product Records relating to periods prior to the Closing in a manner reasonably consistent with the prior practices of Seller; and
(ii) upon reasonable notice, afford Seller’s Representatives reasonable access (including the right to make, at Seller’s expense, photocopies), during normal business hours, to such Product Records.
(b) For any reasonable purpose, for a period of seven years following the Closing, Seller shall:
(i) retain the books and records (including personnel files) of Seller which relate to the Business and its operations for periods prior to the Closing; and
(ii) upon reasonable notice, afford the Buyer’s Representatives reasonable access (including the right to make, at Buyer’s expense, photocopies), during normal business hours, to such books and records.
(c) Neither Buyer nor Seller shall be obligated to provide the other party with access to any books or records (including personnel files) pursuant to this Section 6.04 where such access would violate any Law.
Section 6.05 Public Announcements. Neither party shall issue any press release or make any public announcement concerning this Agreement or the transactions contemplated hereby without the prior written consent of the other party; provided, however, that Buyer may, without the consent of Seller or any other party, issue any such press release, make any such public announcement, or make any filing (including any filings with the U.S. Securities and Exchange Commission) as may be required by applicable Law, legal process, or the rules and regulations of any applicable stock exchange.
| -43- |
Section 6.06 Bulk Sales Laws. The parties hereby waive compliance with the provisions of any bulk sales, bulk transfer, or similar Laws of any jurisdiction that may otherwise be applicable with respect to the sale of any or all of the Acquired Assets to Buyer; it being understood that any Liabilities arising out of the failure of Seller to comply with the requirements and provisions of any bulk sales, bulk transfer, or similar Laws of any jurisdiction which would not otherwise constitute Assumed Liabilities shall be treated as Excluded Liabilities; provided, however, that Seller shall not be required as a condition to Closing to obtain any state, local, or foreign Tax “clearance” or similar certificates.
Section 6.07 Payments Received After Closing. From and after the Closing, if Seller or any of its Affiliates receives or collects any funds relating to any Acquired Asset, Seller or its Affiliate shall remit such funds to Buyer within [***] after its discovery thereof. From and after the Closing, if Buyer or its Affiliate receives or collects any funds relating to any Excluded Asset, Buyer or its Affiliate shall remit any such funds to Seller within [***] after its discovery thereof.
Section 6.08 Transfer Taxes. All transfer, documentary, sales, use, stamp, registration, value added and other such Taxes and fees (including any penalties and interest) incurred in connection with this Agreement and the Ancillary Documents (including any real property transfer Tax and any other similar Tax) shall be borne and paid fifty percent (50%) by Buyer and fifty percent (50%) by Seller when due. Seller shall, at its own expense, timely file any Tax Return or other document with respect to such Taxes or fees (and Buyer shall cooperate with respect thereto as necessary, and shall promptly reimburse Seller for Buyer’s 50% share upon request).
Section 6.09 Control and Development of Products.
(a) From and after the Closing, Buyer shall have sole decision-making authority over the development of the Products, including without limitation Patent strategy, regulatory strategy, CMC, manufacturing, pricing, market access, and commercialization, subject only to Buyer’s obligation to use Commercially Reasonable Efforts, Buyer’s payment obligations related to Royalties and Milestone Payments, if any, and Buyer’s reporting obligations related to the calculation of Royalties and Milestone Payments under Section 2.09 and Section 2.10.
(b) Buyer shall be responsible for funding all Product development, regulatory, CMC, manufacturing and commercialization costs incurred after Closing except for Seller-retained Excluded Liabilities.
(c) Without limiting the foregoing, from and after the Closing until the later of (i) the date on which Buyer confirms in writing that its pharmacovigilance systems are operational for the Product Candidate and (ii) [***] following the Closing Date (or such longer period as the parties may agree in writing), Seller shall continue to collect, process, and report, in accordance with Applicable Regulatory Laws, all adverse events, serious adverse events, and other safety information relating to the Product Candidate, in each case as part of the transition services contemplated by this Section 6.09.
Section 6.10 Further Assurances. Following the Closing, each of the parties hereto shall, and shall cause their respective Affiliates to, execute and deliver such additional documents, instruments, conveyances and assurances, and take such further actions as may be reasonably required to carry out the provisions hereof and give effect to the transactions contemplated by this Agreement and the Ancillary Documents.
| -44- |
Section 6.11 IND Transfer. Following the Closing, each party shall use commercially reasonable efforts to execute and deliver as promptly as practicable following the Closing each notice, letter, instrument, consent, and other document required under Applicable Regulatory Laws to effect the transfer to Buyer of sponsorship of the IND and of the orphan drug designation and the transfer to, or continued availability for, Buyer of all drug master files, letters of authorization, rights of reference, and pharmacovigilance records relating to the Product Candidate, together with such documents, information, and cooperation as is reasonably necessary to permit Buyer to confirm with the FDA the continued applicability of the Fast Track designation following the transfer of IND sponsorship.
ARTICLE VII
RESERVED.
ARTICLE VIII
Indemnification
Section 8.01 Survival. Subject to the limitations and other provisions of this Agreement, the representations and warranties contained herein shall survive the Closing and shall remain in full force and effect until the date that is 18 months from the Closing Date (the “Expiration Date”); provided, that (i) the Fundamental Representations shall survive for the full period of all applicable statutes of limitations (giving effect to any waiver, mitigation or extension thereof) plus [***], (ii) the representations and warranties in Section 4.20 (Taxes) shall survive for the full period of all applicable statutes of limitations (giving effect to any waiver, mitigation or extension thereof) plus [***], and (iii) any representation or warranty to the extent a claim with respect thereto is based on Fraud shall survive indefinitely. All covenants and agreements of the parties contained herein shall survive the Closing until fully performed in accordance with their terms or for the period explicitly specified therein. Notwithstanding the foregoing, any claims asserted in good faith with reasonable specificity (to the extent known at such time) and in writing by notice from the non-breaching party to the breaching party prior to the expiration date of the applicable survival period shall not thereafter be barred by the expiration of the relevant representation or warranty and such claims shall survive until finally resolved.
Section 8.02 Indemnification By Seller. Subject to the other terms and conditions of this Article VIII, including the set-off mechanics set forth in Section 8.06, from and after Closing, Seller shall indemnify and defend each of Buyer and its Affiliates and their respective Representatives (collectively, the “Buyer Indemnitees”) against, and shall hold each of them harmless from and against, and shall pay and reimburse each of them for, any and all Losses incurred or sustained by, or imposed upon, the Buyer Indemnitees based upon, arising out of, with respect to or by reason of:
(a) any inaccuracy in or breach of any of the representations or warranties of Seller contained in this Agreement, the Ancillary Documents or in any certificate or instrument delivered by or on behalf of Seller pursuant to this Agreement, as of the date such representation or warranty was made or as if such representation or warranty was made on and as of the Closing Date (except for representations and warranties that expressly relate to a specified date, the inaccuracy in or breach of which will be determined with reference to such specified date);
(b) any breach or non-fulfillment of any covenant, agreement, or obligation to be performed by Seller pursuant to this Agreement, the Ancillary Documents or any certificate or instrument delivered by or on behalf of Seller pursuant to this Agreement;
(c) any Excluded Asset or any Excluded Liability;
(d) Fraud; or
| -45- |
(e) any Third-Party Claim based upon, resulting from or arising out of the business, operations, properties, assets, or obligations of Seller or any of its Affiliates (other than the Acquired Assets or Assumed Liabilities) conducted, existing or arising on or prior to the Closing Date.
Section 8.03 Indemnification By Buyer. Subject to the other terms and conditions of this Article VIII, from and after Closing, Buyer shall indemnify and defend each of Seller and its Affiliates and their respective Representatives (collectively, the “Seller Indemnitees”) against, and shall hold each of them harmless from and against, and shall pay and reimburse each of them for, any and all Losses incurred or sustained by, or imposed upon, the Seller Indemnitees based upon, arising out of, with respect to or by reason of:
(a) any inaccuracy in or breach of any of the representations or warranties of Buyer contained in this Agreement or in any certificate or instrument delivered by or on behalf of Buyer pursuant to this Agreement, as of the date such representation or warranty was made or as if such representation or warranty was made on and as of the Closing Date (except for representations and warranties that expressly relate to a specified date, the inaccuracy in or breach of which will be determined with reference to such specified date);
(b) any breach or non-fulfillment of any covenant, agreement, or obligation to be performed by Buyer pursuant to this Agreement;
(c) any Assumed Liability;
(d) Fraud; or
(e) any Third-Party Claim based upon, resulting from or arising out of the business, operations, or ownership of the Products or the Acquired Assets by Buyer or any of its Affiliates from and after the Closing Date.
Section 8.04 Certain Limitations. The indemnification provided for in Section 8.02 and Section 8.03 shall be subject to the following limitations:
(a) Seller shall not be liable to the Buyer Indemnitees for indemnification under Section 8.02(a) until the aggregate amount of all Losses in respect of indemnification under Section 8.02(a) exceeds $[***] (the “Basket”), in which event Seller shall be required to pay or be liable for all such Losses [***].
(b) Buyer shall not be liable to the Seller Indemnitees for indemnification under Section 8.03(a) until the aggregate amount of all Losses in respect of indemnification under Section 8.03(a) exceeds the Basket, in which event Buyer shall be required to pay or be liable for all such Losses [***].
(c) Seller’s liability to the Buyer Indemnitees for indemnification under Section 8.02(a) shall not exceed [***]% of the value of the Upfront Shares (valued at the Closing Stock Price) plus [***]% of the value of the aggregate Milestone Payments actually received by Seller prior to the Expiration Date.
(d) Notwithstanding the foregoing, the limitations set forth in Section 8.04(a), Section 8.04(b) and Section 8.04(c) shall not apply to Losses based upon, arising out of, with respect to, or by reason of any inaccuracy in or breach of any Fundamental Representation, any representation or warranty in Section 4.20 (Taxes), Fraud, any Excluded Asset, any Excluded Liability, Section 8.02(b), or Section 8.02(e) (the “Excepted Losses”).
| -46- |
(e) For purposes of this Article VIII (including for purposes of determining the existence of any inaccuracy in, or breach of, any representation or warranty and for calculating the amount of any Loss with respect thereto), any inaccuracy in or breach of any representation or warranty shall be determined without regard to any materiality, Material Adverse Effect or other similar qualification contained in or otherwise applicable to such representation or warranty.
Section 8.05 Indemnification Procedures. The party making a claim under this Article VIII is referred to as the “Indemnified Party”, and the party against whom such claims are asserted under this Article VIII is referred to as the “Indemnifying Party”.
(a) Third-Party Claims. If any Indemnified Party receives notice of the assertion or commencement of any Action made or brought by any Person who is not a party to this Agreement or an Affiliate of a party to this Agreement or a Representative of the foregoing (a “Third-Party Claim”) against such Indemnified Party with respect to which the Indemnifying Party is obligated to provide indemnification under this Agreement, the Indemnified Party shall give the Indemnifying Party reasonably prompt written notice thereof, but in any event not later than [***] after receipt of such notice of such Third-Party Claim. The failure to give such prompt written notice shall not, however, relieve the Indemnifying Party of its indemnification obligations, except and only to the extent that the Indemnifying Party forfeits rights or defenses by reason of such failure. Such notice by the Indemnified Party shall describe the Third-Party Claim in reasonable detail, shall include copies of all material written evidence thereof and shall indicate the estimated amount, if reasonably practicable, of the Loss that has been or may be sustained by the Indemnified Party. The Indemnifying Party shall have the right to participate in, or by giving written notice to the Indemnified Party, to assume the defense of any Third-Party Claim at the Indemnifying Party’s expense and by the Indemnifying Party’s own counsel, and the Indemnified Party shall cooperate in good faith in such defense; provided, that if the Indemnifying Party is Seller, such Indemnifying Party shall not have the right to defend or direct the defense of any such Third-Party Claim that (x) is asserted directly by or on behalf of a Person that is a supplier or customer of the Business, or (y) seeks an injunction or other equitable relief against the Indemnified Party. In the event that the Indemnifying Party assumes the defense of any Third-Party Claim, subject to Section 8.05(b), it shall have the right to take such action as it deems necessary to avoid, dispute, defend, appeal or make counterclaims pertaining to any such Third-Party Claim in the name and on behalf of the Indemnified Party. The Indemnified Party shall have the right to participate in the defense of any Third-Party Claim with counsel selected by it subject to the Indemnifying Party’s right to control the defense thereof. The fees and disbursements of such counsel shall be at the expense of the Indemnified Party, provided, that if in the reasonable opinion of counsel to the Indemnified Party, (A) there are legal defenses available to an Indemnified Party that are different from or additional to those available to the Indemnifying Party; or (B) there exists a conflict of interest between the Indemnifying Party and the Indemnified Party that cannot be waived, the Indemnifying Party shall be liable for the reasonable fees and expenses of counsel to the Indemnified Party in each jurisdiction for which the Indemnified Party determines counsel is required. If the Indemnifying Party elects not to compromise or defend such Third-Party Claim, fails to promptly notify the Indemnified Party in writing of its election to defend as provided in this Agreement, or fails to diligently prosecute the defense of such Third-Party Claim, the Indemnified Party may, subject to Section 8.05(b), pay, compromise, defend such Third-Party Claim and seek indemnification for any and all Losses based upon, arising from or relating to such Third-Party Claim. Seller and Buyer shall cooperate with each other in all reasonable respects in connection with the defense of any Third-Party Claim, including making available (subject to the provisions of Section 6.02) records relating to such Third-Party Claim and furnishing, without expense (other than reimbursement of actual out-of-pocket expenses) to the defending party, management employees of the non-defending party as may be reasonably necessary for the preparation of the defense of such Third-Party Claim.
| -47- |
(b) Settlement of Third-Party Claims. Notwithstanding any other provision of this Agreement, the Indemnifying Party shall not enter into settlement of any Third-Party Claim without the prior written consent of the Indemnified Party, not to be unreasonably withheld, conditioned or delayed, except as provided in this Section 8.05(b). If a firm offer is made to settle a Third-Party Claim without leading to Liability or the creation of a financial or other obligation on the part of the Indemnified Party and provides, in customary form, for the unconditional release of each Indemnified Party from all Liabilities and obligations in connection with such Third-Party Claim and the Indemnifying Party desires to accept and agree to such offer, the Indemnifying Party shall give written notice to that effect to the Indemnified Party. If the Indemnified Party fails to consent to such firm offer within [***] after its receipt of such notice, the Indemnified Party may continue to contest or defend such Third-Party Claim and in such event, the maximum liability of the Indemnifying Party as to such Third-Party Claim shall not exceed the amount of such settlement offer. If the Indemnified Party fails to consent to such firm offer and also fails to assume defense of such Third-Party Claim, the Indemnifying Party may settle the Third-Party Claim upon the terms set forth in such firm offer to settle such Third-Party Claim. If the Indemnified Party has assumed the defense pursuant to Section 8.05(a), it shall not agree to any settlement without the written consent of the Indemnifying Party (which consent shall not be unreasonably withheld, conditioned or delayed).
(c) Direct Claims. Any Action by an Indemnified Party on account of a Loss which does not result from a Third-Party Claim (a “Direct Claim”) shall be asserted by the Indemnified Party giving the Indemnifying Party reasonably prompt written notice thereof, but in any event not later than [***] after the Indemnified Party becomes aware of such Direct Claim. The failure to give such prompt written notice shall not, however, relieve the Indemnifying Party of its indemnification obligations, except and only to the extent that the Indemnifying Party forfeits rights or defenses by reason of such failure. Such notice by the Indemnified Party shall describe the Direct Claim in reasonable detail, shall include copies of all material written evidence thereof and shall indicate the estimated amount, if reasonably practicable, of the Loss that has been or may be sustained by the Indemnified Party. The Indemnifying Party shall have [***] after its receipt of such notice to respond in writing to such Direct Claim. The Indemnified Party shall allow the Indemnifying Party and its professional advisors to investigate the matter or circumstance alleged to give rise to the Direct Claim, and whether and to what extent any amount is payable in respect of the Direct Claim and the Indemnified Party shall assist the Indemnifying Party’s investigation by giving such information and assistance (including access to the Indemnified Party’s premises and personnel and the right to examine and copy any accounts, documents or records) as the Indemnifying Party or any of its professional advisors may reasonably request. If the Indemnifying Party does not so respond within such 30-day period, the Indemnifying Party shall be deemed to have rejected such claim, in which case the Indemnified Party shall be free to pursue such remedies as may be available to the Indemnified Party on the terms and subject to the provisions of this Agreement.
Section 8.06 Payments; Indemnification Set-Off.
(a) Once a Loss is agreed to by the Indemnifying Party or finally adjudicated to be payable pursuant to this Article VIII, the Indemnifying Party, if Buyer, shall satisfy its obligations within [***] of such agreement or final, non-appealable adjudication by wire transfer of immediately available funds or, if the Indemnifying Party is Seller, the obligations shall be satisfied as provided in Section 8.06(b). The parties hereto agree that should Buyer not make full payment of any such obligations within such 15 Business Day period, any amount payable shall accrue interest from and including the date of agreement of the Indemnifying Party or final, non-appealable adjudication to the date such payment has been made at a rate per annum equal to 12%. Such interest shall be calculated daily on the basis of a 365-day year and the actual number of days elapsed.
| -48- |
(b) Any Losses payable to a Buyer Indemnitee pursuant to this Article VIII shall be satisfied, at the election of Seller, by set-off against the aggregate Milestone Payments actually received by Seller, and by set-off against the Upfront Shares (based on a value per Upfront Share equal to the Closing Stock Price), or a combination of such remedies, subject to the limitations in this Article VIII, it being understood that in no event shall Buyer be entitled to recover Excepted Losses in excess of the aggregate Milestone Payments actually received by Seller plus the value of the Upfront Shares. In the event Seller is required to make any payment to a Buyer Indemnitee under this Article VIII, such payment shall be made in accordance with the payment deadline, and subject to the late payment interest provisions, in Section 8.06(a).
Section 8.07 Tax Treatment of Indemnification Payments. All indemnification payments made under this Agreement shall be treated by the parties as an adjustment to the Purchase Price for Tax purposes, unless otherwise required by Law.
Section 8.08 Application of Indemnification upon Distribution. Upon receipt of a Distribution and execution of a Distribution Joinder, the provisions of this Article VIII shall apply, mutatis mutandis, to the Distribution Recipient as an Indemnifying Party with respect to the obligations of Seller under Section 8.02 and as a Seller Indemnitee under Section 8.03, subject in each case to the express limitations of this Section 8.08. Each Distribution Recipient’s liability shall be several and not joint with Seller or any other Person. No Distribution Recipient shall be liable for any other Person’s failure to pay, and no shortfall attributable to another Person shall increase its liability. Receipt of a Distribution shall not, by itself, cause a Distribution Recipient to make or repeat any representation or warranty of Seller or become subject to any covenant of Seller outside this Article VIII, other than the express obligations assumed under this Section and its Distribution Joinder. Notwithstanding anything in this Section 8.08 to the contrary, Seller shall remain obligated for the full amount of all indemnification obligations under this Article VIII and any Distribution shall not release Seller from such obligations.
For each Loss otherwise indemnifiable under Section 8.02, a Distribution Recipient shall in no event be responsible for more than its Pro Rata Percentage of the amount of that Loss recoverable under this Article VIII after application of the Basket, applicable caps and all other limitations, determined once on an aggregate basis as if no Distribution had occurred. “Pro Rata Percentage” means the percentage of Seller’s original economic entitlement to the Purchase Price represented by the consideration distributed to the Distribution Recipient, traced through each tier of Distribution without duplication. For a Distribution of Upfront Shares or their proceeds, such percentage equals the number of original Upfront Shares represented by the Distribution divided by the total number of Upfront Shares issued at Closing; proceeds shall retain the percentage attributable to the underlying shares. For a Distribution of Milestone Payments, such percentage equals the Distribution Recipient’s distributed interest in those payments as a percentage of Seller’s original entitlement to those payments. If different percentages apply to different components of consideration, the Distribution Recipient’s percentage shall be the weighted average of those percentages based on the aggregate value of the Upfront Shares issued at Closing and Milestone Payments actually received by Seller as of the determination, using the Closing Stock Price for the shares. The applicable calculations shall be reflected in the distribution schedules delivered to Buyer and updated for additional Distribution Recipients. No payment shortfall or Distribution to another Person shall increase a Distribution Recipient’s allocated percentage.
| -49- |
In no event shall a Distribution Recipient’s aggregate liability arising out of or relating to this Agreement, any Distribution or any Distribution Joinder, including for Excepted Losses, breaches of Fundamental Representations, other special indemnities, interest and enforcement costs, exceed the value of the consideration actually received by it in Distributions (its “Recipient Consideration Value”). Upfront Shares shall be valued at the Closing Stock Price, equitably adjusted for subsequent stock splits, reverse stock splits, stock dividends, reclassifications or similar events, and cash shall be valued at the amount received. Proceeds of Upfront Shares shall be assigned the Closing Stock Price value of the original shares represented thereby. The same shares and their proceeds shall not be counted twice for any recipient. The limitations otherwise applicable under this Article VIII, including the cap in Section 8.04(c) for non-Excepted Losses, shall apply collectively to Seller and all Distribution Recipients, and shall not be multiplied by the number of recipients or tiers.
Section 8.09 Exclusive Remedies. Subject to and except for Section 2.09, Section 2.10 and Section 10.11, the parties acknowledge and agree that from and after Closing their sole and exclusive remedy with respect to any and all claims (other than claims arising from Fraud on the part of a party hereto in connection with the transactions contemplated by this Agreement) for any breach of any representation, warranty, covenant, agreement or obligation set forth herein or otherwise relating to the subject matter of this Agreement, shall be pursuant to the indemnification provisions set forth in this Article VIII. In furtherance of the foregoing, except with respect to Section 2.09, Section 2.10, and Section 10.11, each party hereby waives, from and after Closing, to the fullest extent permitted under Law, any and all rights, claims and causes of action for any breach of any representation, warranty, covenant, agreement or obligation set forth herein or otherwise relating to the subject matter of this Agreement it may have against the other parties hereto and their Affiliates and each of their respective Representatives arising under or based upon any Law, except pursuant to the indemnification provisions set forth in this Article VIII. Nothing in this Section 8.09 shall limit any Person’s right to seek and obtain any equitable relief to which any Person shall be entitled or to seek any remedy on account of any party’s Fraud against such party.
ARTICLE IX
reserved
ARTICLE X
Miscellaneous
Section 10.01 Expenses. Except as otherwise expressly provided herein, all costs and expenses, including, without limitation, fees and disbursements of counsel, financial advisors and accountants, incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the party incurring such costs and expenses, whether or not the Closing shall have occurred; provided, however, Buyer shall reimburse Seller for its reasonable and documented transaction expenses up to an aggregate amount of $500,000 (the “Expense Reimbursement”), which reimbursement shall be due and payable at the Closing.
| -50- |
Section 10.02 Notices. All notices, requests, consents, claims, demands, waivers and other communications hereunder shall be in writing and shall be deemed to have been given (a) when delivered by hand (with written confirmation of receipt); (b) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested); (c) on the date sent by e-mail (unless automatically returned to the sender as undeliverable) if sent during normal business hours of the recipient, and on the next Business Day if sent after normal business hours of the recipient or (d) on the third day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Such communications must be sent to the respective parties at the following addresses (or at such other address for a party as shall be specified in a notice given in accordance with this Section 10.02):
| If to Seller: | Ellodi Pharmaceuticals, L.P. | |
| [***] | ||
| Attention: [***] | ||
| President | ||
| Email: [***] | ||
| with a copy to: | Cooley LLP | |
| 500 Boylston Street, 14th Floor | ||
| Boston, MA 02116-3736 | ||
| Attention: Miguel J. Vega | ||
| Email: mvega@cooley.com | ||
| If to Buyer: | Abeona Therapeutics Inc. | |
| 6555 Carnegie Avenue, 4th Floor | ||
| Cleveland, OH 44103 | ||
| Attention: [***] | ||
| Chief Legal Officer | ||
| Email: [***] | ||
| with a copy to: | Carlton Fields, P.A. | |
| 4221 Boy Scout Blvd., Ste. 1000 | ||
| Tampa, FL 33607-5780 | ||
| Attention: Brian V. Soares | ||
| Email: BSoares@carltonfields.com |
Section 10.03 Interpretation. For purposes of this Agreement, unless otherwise expressly provided, (a) the words “include,” “includes” and “including” shall be deemed to be followed by the words “without limitation”; (b) the word “or” is not exclusive; (c) the words “herein,” “hereof,” “hereby,” “hereto” and “hereunder” refer to this Agreement as a whole; and (d) references herein: (i) to Articles, Sections, Disclosure Schedules and Exhibits mean the Articles and Sections of, and Disclosure Schedules and Exhibits attached to, this Agreement; (ii) to an agreement, instrument or other document means such agreement, instrument or other document as amended, supplemented and modified from time to time to the extent permitted by the provisions thereof and (iii) to a statute means such statute as amended from time to time and includes any successor legislation thereto and any regulations promulgated thereunder. Wherever the context so requires or permits, the use of the singular form includes the plural, and the use of the plural form includes the singular; and the use of any pronoun or gendered term includes the masculine, feminine, and neuter forms as the identity of the parties or context may require. This Agreement shall be construed without regard to any presumption or rule requiring construction or interpretation against the party drafting an instrument or causing any instrument to be drafted. The Disclosure Schedules and Exhibits referred to herein shall be construed with, and as an integral part of, this Agreement to the same extent as if they were set forth verbatim herein.
Section 10.04 Headings. The headings in this Agreement are for reference only and shall not affect the interpretation of this Agreement.
| -51- |
Section 10.05 Severability. If any term or provision of this Agreement is invalid, illegal, or unenforceable in any jurisdiction, such invalidity, illegality, or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction. Except as provided in Section 6.03(d), upon such determination that any term or other provision is invalid, illegal or unenforceable, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the greatest extent possible.
Section 10.06 Entire Agreement. This Agreement and the Ancillary Documents constitute the sole and entire agreement of the parties to this Agreement with respect to the subject matter contained herein and therein, and supersede all prior and contemporaneous understandings and agreements, both written and oral, with respect to such subject matter. In the event of any inconsistency between the statements in the body of this Agreement and those in the Ancillary Documents, the Exhibits and Disclosure Schedules (other than an exception expressly set forth as such in the Disclosure Schedules), the statements in the body of this Agreement will control.
Section 10.07 Successors and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns. Neither party may assign its rights or obligations hereunder to a non-Affiliate without the prior written consent of the other party, which consent shall not be unreasonably withheld, conditioned or delayed; provided, however, that prior to the Closing Date, Buyer may, without the prior written consent of Seller, assign all or any portion of its rights under this Agreement to one or more of its direct or indirect wholly-owned subsidiaries, provided further that no such assignment shall relieve Buyer of any of its obligations hereunder. No assignment shall relieve the assigning party of any of its obligations hereunder.
Section 10.08 No Third-Party Beneficiaries. Except as provided in Article VIII, this Agreement is for the sole benefit of the parties hereto and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other Person any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.
Section 10.09 Amendment and Modification; Waiver. This Agreement may only be amended, modified, or supplemented by an agreement in writing signed by each party hereto. No waiver by any party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the party so waiving. No waiver by any party shall operate or be construed as a waiver in respect of any failure, breach or default not expressly identified by such written waiver, whether of a similar or different character, and whether occurring before or after that waiver. No failure to exercise, or delay in exercising, any right, remedy, power or privilege arising from this Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.
Section 10.10 Governing Law; Submission to Jurisdiction; Waiver of Jury Trial.
(a) This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction).
| -52- |
(b) ANY LEGAL SUIT, ACTION OR PROCEEDING ARISING OUT OF OR BASED UPON THIS AGREEMENT, THE ANCILLARY DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY MAY BE INSTITUTED IN THE FEDERAL COURTS OF THE UNITED STATES OF AMERICA OR THE COURTS OF THE STATE OF DELAWARE IN EACH CASE LOCATED IN THE CITY OF WILMINGTON AND COUNTY OF NEW CASTLE, AND EACH PARTY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF SUCH COURTS IN ANY SUCH SUIT, ACTION OR PROCEEDING. SERVICE OF PROCESS, SUMMONS, NOTICE OR OTHER DOCUMENT BY MAIL TO SUCH PARTY’S ADDRESS SET FORTH HEREIN SHALL BE EFFECTIVE SERVICE OF PROCESS FOR ANY SUIT, ACTION OR OTHER PROCEEDING BROUGHT IN ANY SUCH COURT. THE PARTIES IRREVOCABLY AND UNCONDITIONALLY WAIVE ANY OBJECTION TO THE LAYING OF VENUE OF ANY SUIT, ACTION OR ANY PROCEEDING IN SUCH COURTS AND IRREVOCABLY WAIVE AND AGREE NOT TO PLEAD OR CLAIM IN ANY SUCH COURT THAT ANY SUCH SUIT, ACTION OR PROCEEDING BROUGHT IN ANY SUCH COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM.
(c) EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT OR THE ANCILLARY DOCUMENTS IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LEGAL ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE ANCILLARY DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. EACH PARTY TO THIS AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER IN THE EVENT OF A LEGAL ACTION, (B) SUCH PARTY HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) SUCH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (D) SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 10.10(c).
Section 10.11 Specific Performance. Except as otherwise expressly provided herein (including, without limitation, Section 8.09), any and all remedies provided herein will be deemed cumulative with and, unless otherwise expressly set forth herein, not exclusive of any other remedy conferred hereby, or by Law or equity upon such party, and the exercise by a party of any one remedy shall not preclude the exercise of any other remedy. Irreparable damage for which monetary damages would not be an adequate remedy would occur if the parties fail to perform their obligations under this Agreement or otherwise breach its provisions. The parties agree that, in the event of any breach or threatened breach by any other party or parties, of any covenant, obligation or other agreement set forth in this Agreement, (i) each party shall be entitled, without any proof of actual damages (and in addition to any other remedy that may be available to it), to a decree or order of specific performance or mandamus to enforce the observance and performance of such covenant, obligation or other agreement and an injunction preventing or restraining such breach or threatened breach, and (ii) no party shall be required to provide or post any bond or other security or collateral in connection with any such decree, order or injunction or in connection with any related action or legal proceeding. Subject to the terms and conditions set forth in this Agreement, each of the parties agrees that it will not oppose the granting of an injunction, specific performance and other equitable relief on the basis that the other parties have an adequate remedy at law or an award of specific performance is not an appropriate remedy for any reason at law or equity.
Section 10.12 Non-Reliance. Each party acknowledges and agrees that, in entering into this Agreement, it has not relied on any representation, warranty, statement, opinion, projection, forecast or other information of any kind, written or oral, made or furnished by or on behalf of any other party or any of its Representatives, except for the representations and warranties of such other party expressly set forth in Article IV or Article V, as applicable, this Agreement, the Ancillary Documents, and the certificates delivered pursuant hereto and thereto. Each party, on behalf of itself and its Affiliates, hereby disclaims reliance on any other representations or warranties, whether written or oral, including any made in any management presentation, due diligence response, data room or other materials made available in connection with the transactions contemplated by this Agreement.
Section 10.13 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by email or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.
[signature page follows]
| -53- |
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date first written above by their duly authorized officers.
| SELLER: | ||
| Ellodi Pharmaceuticals, L.P. | ||
| By: | ||
| Name: | ||
| Title: | ||
[Signature Page to Asset Purchase Agreement]
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date first written above by their duly authorized officers.
| BUYER: | ||
| Abeona Therapeutics Inc. | ||
| By: | ||
| Name: | ||
| Title: | ||
[Signature Page to Asset Purchase Agreement]
EXHIBIT A
Registration Rights Agreement
EXHIBIT B
Distribution Joinder